Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 17, 2026.

The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents

Jiabei Zhou, Yu Kang, Lu Chen and 4 more (opens in a new tab)

Frontiers in Pharmacology · 2020 · Review · CC BY

doi:10.3389/fphar.2020.00343 (opens in a new tab)

Abstract

Platinum-based anticancer drugs, including cisplatin, carboplatin, oxaliplatin, nedaplatin, and lobaplatin, are heavily applied in chemotherapy regimens. However, the intrinsic or acquired resistance severely limit the clinical application of platinum-based treatment. The underlying mechanisms are incredibly complicated. Multiple transporters participate in the active transport of platinum-based antitumor agents, and the altered expression level, localization, or activity may severely decrease the cellular platinum accumulation. Detoxification components, which are commonly increasing in resistant tumor cells, can efficiently bind to platinum agents and prevent the formation of platinum-DNA adducts, but the adducts production is the determinant step for the cytotoxicity of platinum-based antitumor agents. Even if adequate adducts have formed, tumor cells still manage to survive through increased DNA repair processes or elevated apoptosis threshold. In addition, autophagy has a profound influence on platinum resistance. This review summarizes the critical participators of platinum resistance mechanisms mentioned above and highlights the most potential therapeutic targets or predicted markers. With a deeper understanding of the underlying resistance mechanisms, new solutions would be produced to extend the clinical application of platinum-based antitumor agents largely.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Ever since cisplatin, the first generation of platinum antitumor agents, was approved by the U.S. Food and Drug Administration for the treatment of testicular cancer, the development of platinum antitumor agents has explosively grown during the last forty years. The second-generation product carboplatin and the third-generation product oxaliplatin were approved worldwide in succession with enlarged spectrum or decreased toxicity. Till today, cisplatin, carboplatin, and oxaliplatin are still extensively applied in the treatment of cancer.

Cisplatin (Figure 1) is a neutral, square planar coordination complex of platinum(II) coordinated to two chloride and two ammonia groups, where the chloride ligands are in the cis-geometry. Once inside the cell, cisplatin undergoes aquation to form [Pt(NH3)2Cl(OH2)]+ and [Pt(NH3)2(OH2)2]2+, therefore, it becomes more reactive to DNA. It is approved for the treatment of advanced pancreatic cancer, breast cancer, non-small cell lung cancer (NSCLC), advanced bladder cancer et al. In the second-generation products, two chloride atoms are replaced by an oxygenated bidendate cyclobutane-dicarboxylate group to form carboplatin (cis-diammine-1,1′-cyclobutane dicarboxylate platinum II, Figure 1), which is easier to administrate and less toxic compared with cisplatin. However, carboplatin has a similar anticancer spectrum with cisplatin, and the cross-resistance with cisplatin is observed in many cancer types. Oxaliplatin ({[oxalate(2-)-O, O′][1R,2R-cyclohexanediamine-N, N’] platinum-(II)}, Figure 1) belongs to the third generation of platinum-based antitumor agents, in which 1, 2-diaminocyclohexane (DACH) ligand substitutes for the amine groups of cisplatin. It was reported that oxaliplatin could produce fewer DNA adducts but caused higher cytotoxicity than cisplatin, and it also shows stronger activity in colorectal and other gastrointestinal cancers, while cisplatin and carboplatin show no efficacy. Nedaplatin (cis-diammine (glycolato-O¹, O²)platinum, Figure 1), the second-generation platinum analogue, was first approved in Japan. It has approximately ten times as soluble in water as cisplatin and lower toxicity than cisplatin. Nedaplatin shows promising results in combination therapies. Lobaplatin (cis-[trans-1,2-cyclobutanebis(methylamine)][(S)-lactato-O1, O2]platinum(II), Figure 1), the third-generation platinum analogue, was approved in China for treatment of breast cancer, NSCLC, and chronic myelocytic leukemia.

It’s common to see patients who respond well to platinum treatment become resistant to platinum-based chemotherapy in a short time. The resistance result from (i) reduced cellular drug accumulation, (ii) increased detoxification system, (iii) increased DNA repair process, (iv) decreased apoptosis, and (v) autophagy as summarized in Figure 2. This work reviews the updated platinum-resistance mechanisms and the key participators.

Transporters Involved in Platinum Influx/Efflux

The accumulation of platinum antitumor agents inside the cells is the necessary assurance of cytotoxicity, so decreased influx or increased efflux is responsible for platinum resistance. For many years it has been assumed that platinum enters cells by passive diffusion and through gated channels. However, the role of active transport mediated by multiple transporters become prominent to platinum-uptake. Three urgent questions need explanations: (i) which transporters are responsible for platinum-uptake, (ii) how transporters change during drug-resistance development, and (iii) what can be done to reverse resistance by targeting transporters.

Solute Carrier Superfamily of Membrane Transporters

The solute carrier superfamily (SLCs) contains more than 300 members and 65 subfamilies such as the organic anion transporting polypeptides, organic anion transporters, and organic cation transporters (OCTs). Normally SLCs are expressed in the whole body to sustain the cellular homeostasis by mediating the transportation of endogenous substances and exogenous substances. However, the expression or the distribution of SLCs may change under the disease condition or due to the drug–drug interaction effect, and it will have a significant effect on the cellular uptake of therapeutic drugs then leads to the unsatisfied results.

Cisplatin is a substrate of hOCT1 (SLC22A1), hOCT2 (SLC22A2), and hMATE1 (SLC47A1), and oxaliplatin is a substrate of hOCT2, hOCT3 (SLC22A3), hMATE1 (SLC47A1), and hMATE2-K (SLC47A2). Carboplatin and Nedaplatin are not transported by the transporters mentioned above. However, some contradictory results were reported probably because of the different selection of verification models, as summarized in Table 1. The down-regulation, mislocation, or inhibited transport activity of OCTs can all reduce the intracellular platinum concentration. Gao et al. reported that omeprazole could decrease the protein level of OCT2, thus lead to reduced cellular accumulation of cisplatin. employed a novel fluorescent oxaliplatin derivative to discovered that OCT1 involves in oxaliplatin uptake in the sensitive but not in the resistant cell line, which may be a consequence of the altered localization of the transporter in resistant cells rather than the lower expression. Recent studies reported two crucial regulatory mechanisms of OCTs: phosphotyrosine-mediated activity regulation and epigenetic regulation. Sprowl and colleagues revealed that the phosphorylation status of Y362, mediated by the Src family kinase Yes1, might be essential for OCT2 function; hence tyrosine kinase inhibitor like dasatinib can inhibit oxaliplatin uptake and mitigate oxaliplatin-induced acute sensory neuropathy. Our previous work revealed the link between the epigenetic changes of OCT2 and oxaliplatin resistance in renal cell carcinoma (RCC). We found that hypermethylated CpG islands of OCT2 disrupted the interaction between MYC and the E-Box motif, further it would prevent MYC recruiting MLL1 to catalyze H3K4me3 at the OCT2 promoter. As a consequence, the transcriptional repression of OCT2 diminished oxaliplatin accumulation and failed the oxaliplatin treatment in RCC. But decitabine, a demethylating reagent, can efficiently reverse the hypermethylation of OCT2. Therefore, the combination therapy of decitabine and oxaliplatin is a promising treatment option to reactivate RCC to oxaliplatin. The results indicated that OCT2 demethylation cracks open oxaliplatin resistance in RCC and it highlights the huge potentiality of targeting transporters in clinical application.

Copper Transporter 1/2

Copper transporter 1 (CTR1) ubiquitously expresses in tissues and is required for high-affinity copper uptake. It is widely acknowledging that CTR1 transports cisplatin, oxaliplatin, and carboplatin. Deletion of the yeast CTR1 gene reduces the intracellular accumulation of cisplatin and leads to cisplatin-resistance, while forced overexpression of hCTR1 sensitizes small cell lung cancer cells to cisplatin, carboplatin, and oxaliplatin. Therefore, hCTR1 has the potentiality to become a hopeful biomarker for platinum-based chemotherapy. It can be down-regulated by intracellular copper or cisplatin/oxaliplatin treatment which triggers a rapid loss of hCTR1 via macropinocytosis and proteasomal degradation in ovarian carcinoma cells and hepatocellular carcinoma cells. Ishida et al. shown that copper chelator tetrathiomolybdate could increase the uptake of cisplatin into tumor cells specifically, and so did Fu and coworkers. They reported a combined therapy of carboplatin and trientine, a copper-lowering agent, partly reversed resistance to platinum therapy on five patients with platinum-resistant high-grade epithelial ovarian cancer. The proteasome inhibitors bortezomib and natural compound β-elemene were also discovered that could block CTR1 from degradation. However, a lot of conflicting conclusions of whether regulating CTR1 levels affects sensitivity to platinum-based drugs have emerged. Kristin et al. knocked out the CTR1, CTR2, ATOX1, and CCS using CRISPR-Cas9 genome editing; and the results indicated that the loss of CTR1, CTR2, ATOX1, or CCS had little impact on cisplatin sensitivity in both human HEK-293T and ovarian carcinoma OVCAR8 cells. Another research found that overexpression of CTR1 failed to increase platinum accumulation and had no effect on the sensitivity of cisplatin in DLD-1 cells. The clinical relevance of hCTR1 and platinum-based chemotherapy has been questioned as well.

CTR2 is a low-affinity transporter of copper that shares 41% amino acid homology and the similar essential domains for copper transport with CTR1 except for the extended N-terminal domain. It locates at late endosomes and lysosomes, although it had also been found on the plasma membrane. The mRNA and protein levels of hCTR2 have significant correlations with the sensitivity of cisplatin. Knocking down CTR2 in some cells increases the cellular accumulation of cisplatin, yet overexpressing the CTR2 reduces the sensitivity to cisplatin. Blair et al. indicated that CTR2 regulated the accumulation of cisplatin through an effect on macropinocytosis, not by changing drug efflux or microsomal storage. Moreover, CTR2 can interact with CTR1 via stimulating CTR1 ectodomain cleavage resulting in less accumulation of cisplatin in cells.

ATP7A and ATP7B

ATP7A/7B, which belongs to P-type ATPases, is responsible for copper homeostasis. After getting into the cells, platinum may bind to the CXXC motifs of ATP7A/B, then the complex translocates into a vesicle in an ATP-dependent manner with the association of copper chaperone Atox1. ATP7A/B resides in the trans-Golgi network under normal conditions, but in platinum-resistance cells, it distributes in more peripherally located vesicles in the cytosol. The altered localization may be caused by reduced lysosomal compartment, and it contributes to platinum-sequestration. ATP7A acts as an insulator, keeping cisplatin away from nuclear in resistance cells. Chisholm and coworkers observed that the cellular platinum intensity is low and is excluded from the nucleus when it shows high expression. ATP7B is also regarded as a contributor to platinum resistance and may serve as a prognostic factor. Patients with the lowest mRNA expression levels of ATP7B presented a significantly longer time to progression and had the optimal curative effects from oxaliplatin/5FU treatment in colorectal cancer. Given the above, it seems that downregulating ATP7A/B could be an effective way to overcome the resistance in tumor cells. By direct binding to 3′ untranslated region (3′ UTR) of the ATP7A/B mRNA, some microRNAs (miRNA, miR) regulates the cell response to cisplatin, carboplatin, and oxaliplatin such as miR-495, miR-139, and miR-133a. The copper chelator ammonium tetrathiomolybdate ([(NH4)2MoS4], TM) can also restore the sensitivity to cisplatin by inducing dimerization of the metal-binding domain of ATP7B.

Multidrug Resistance Protein Subfamily

Multidrug resistance protein (MRP, ABCC) subfamily, which has seven subfamilies named A to G, belongs to the ATP-binding cassette transporter superfamily and functions as an ATP-dependent unidirectional efflux pump for anionic amphiphilic compounds. MRPs mediated the efflux of endogenous molecules, physiological substrate, and drugs (reviewed in ). MRP2, not MRP1 or MDR1, has long been recognized as the efflux transporter of the platinum-GSH conjugate. High-level expression of MRP2 is associated with intrinsic cisplatin resistance and clinical outcome in small cell lung carcinoma, ovarian cancer, and esophageal squamous cell carcinoma. MRP4 has also been identified as a platinum resistance-associated candidate. The overexpression of MRP4 is related to cisplatin resistance, and knocking down MRP4 instead of MRP1 increases the accumulation of oxaliplatin and cisplatin.

Glutathione

Glutathione (L-γ-glutamyl-l-cysteinyl-glycine, GSH) plays a vital role in the cellular redox state via scavenging free radicals, defending cells against xenobiotics and maintaining the sulfhydryl groups of many proteins. The active SH-group of GSH has a high affinity to platinum, thus makes GSH become an easy, non-DNA-related target. The GS-platinum complex catalyzed by glutathione-S-transferase can reach to about 60% of the intracellular platinum content after 12-h incubation in leukemia cells, and the elevated expression of GSH and glutathione-S-transferase are often seen in the resistant-cells. Preventing the formation of the GS-platinum complex may reverse the platinum resistance efficiently. One choice is to use competitive inhibitors of GSH such as [Cu(phen)(H2O)2(ClO4)2] (C10), another is to interfere with the synthesis of GSH. Two enzymes mediate the production of GSH, γ-glutamylcysteine ligase and GSH synthetase. In the first step, γ-glutamylcysteine ligase catalyze glutamate and cysteine to form γ-glutamylcysteine; then, in the second step, GSH synthetase catalyzes γ-glutamylcysteine and glycine to form GSH. GSH-depleting agents buthionine sulfoximine is a useful agent for inhibition of γ-glutamylcysteine ligase, and it reduced the resistance to cisplatin in malignant glioma. However, non-specific GSH depletion can cause irreversible damage in most normal tissues. Hence selective tumor GSH depletion appears to be a better choice but remains as a superb challenge (reviewed in ). Cystine is normally used as the precursor for GSH synthesis due to the chemical instability of cysteine, and the intracellular cysteine/cystine level is maintained by the xc− system which mediates the uptake of cystine; so finding ways to inhibit xc− system can block the synthesis of GSH. Sulfasalazine and salubrinal are both reported as powerful blockers. Epigenetic interference also involves in the regulation of the GSH synthesis: miRNA-27a negatively regulates the xc-; G9a, a transcriptional corepressor that catalyzes histone 3 lysine 9 dimethylation, transcriptional activates the glutamate-cysteine ligase catalytic subunit, and lead to the elevation of GSH level in head and neck squamous cell carcinoma; Linc RNA (Lnc RNA, Lnc) H19 participates in the production and regeneration of GSH in high-grade serous ovarian cancer.

GSH redox cycle also regulates platinum resistance. GSH can be oxidized into GSSG by GSH peroxidase using H2O2 as a substrate, whereas GSSG can be reduced back to GSH by GSSG reductase using NADPH as a cofactor. Higher expression of glutathione reductase accompanied by lower levels of endogenous reactive oxygen species (ROS) contributes to the cisplatin-resistance.

Metallothionein

Platinum antitumor drugs are also inactivated by chelating with metallothionein (MT) proteins. MTs are low-molecular-weight metal-binding proteins containing one-third cysteine residues, which make MTs become easy targets for platinum to chelate. Platinum agents may also bind to metal transcription inhibitor and release the metal transcription factor-1 to trigger the biosynthesis of MTs. It has been found that MTs level is increased not only in the tumor tissue but also in the serum of cancer patients; RNA interference can inhibit the overexpression of MTs efficiently and reverse platinum resistance. Expressing level of the MTs has been considered as an important biological factor of platinum-based chemotherapy, but rather than global MTs classes, Habel and colleagues suggested that MT isoforms are more valuable prognosis predictors markers. Pekarik et al. noted that MT-1 and MT-2 have redundant binding sites for many miRNAs, including miR23 and miR224. It indicated that miRNAs may involve in the regulation of MTs, and could be a notable pointcut.

DNA Repair

The platinum atom can covalently bound to the N7 positions of purine bases to form the platinum–DNA adducts. Cisplatin can form mono adducts, intrastrand, or interstrand cross-links, but the 1,2-intrastrand crosslinks account for over 90% (reviewed in; ). It is well acknowledged that forming DNA adducts is the determinant step for cytotoxicity of platinum-based antitumor agents because the platinum–DNA complexes influence the structure of DNA double helix and nucleosomes. As a result, it causes replication and transcription inhibition and DNA double-strand breaks (DSBs), followed by the initiation of DNA repair. Once the DNA repair fails or is overwhelmed by too many DNA lesions, cell death will be triggered (reviewed in ). The increased DNA repair process is considered as the most significant characteristic in platinum-resistance cells, with the exception of DNA mismatch repair whose deficiency gives rise to cisplatin/carboplatin resistance, but has less influence to oxaliplatin. Oxaliplatin has more potent cytotoxicity than cisplatin for inducing early secondary DSBs and massive apoptosis. However, Bruno et al. reported that oxaliplatin induces ribosome biogenesis stress rather than DNA damage to kill cells. Most intrastrand crosslinks are removed by nucleotide excision repair (NER) system via excising damaged nucleotides and synthesizing DNA to reconstitute genetic integrity, while other lesions are repaired by complex-combined mechanisms. Only two key components of the DNA repair system will be discussed in this review.

Excision Repair Cross-Complementing

All excision repair cross-complementing (ERCC) members have their unique roles in DNA repair progress, and their expression level or SNP has a significant impact on platinum resistance. In a prospective study, Sullivan et al. analyzed the SNPs in eight DNA-repair related genes and found that after the treatment of platinum-based chemotherapy, the response of patients with stages III significantly associated with SNPs in ERCC1 and ERCC3 genes, while the response of patients with stage IV associated with a genetic variant in the ERCC4 gene. Many researchers highlight the relevance between ERCC1 and platinum-treatment response. Liu et al. found that under DNA damage condition, p53 recruited CITED2/P300 along with chromatin relaxation H3K9Ac or H3K14Ac to bind with the ERCC1 promotor, and activated the DNA repair process. However, Spada et al. reported that ERCC1 had no significant correlation with the clinical outcome with oxaliplatin-based chemotherapy in advanced neuroendocrine tumors. ERCC4 (XPF), a necessary component in NER, interstrand cross-links repair, homologous recombination repair (HRR) but not in non-homologous end-joining, contributes to the intrinsic resistance of cisplatin, and its expression level is tissue-specific. ERCC1 and XPF can form the human ERCC1–XPF complex which works as a nuclease in NER and the late stage of HRR. Arora et al. reported that knocking down ERCC1–XPF resulted in reduced intrastrand repair and interstrand crosslinks repair, which makes about fourfold to sixfold changes in IC50 value of cisplatin in NSCLC cells. Based on the above results, it is reasonable to believe that inhibiting ERCC1/XPF is a potential way to sensitize tumor cells to platinum-based chemotherapy, and many inhibitors are discovered: green tea polyphenol epigallocatechin-3-gallate, catechols, 3-hydroxypyridones, N-hydroxyimides, and hydroxypyrimidones, but their clinical application still needs further investigation. Another nuclease function as ERCC1–XPF in NER is ERCC5 (XPG), which also relates to platinum sensitivity. Graf et al. reported that XPF and XPG knockdown increased the platinum-induced cytotoxicity in osteosarcoma cells. Interestingly, platinum-based chemotherapy is influenced by the 5′ noncoding mRNA element of ERCC5. Somers’s group discovered a common polymorphic variant rs751402 in the ERCC5 5′ untranslated region, which generated an upstream ORF, and the carriers with early childhood ependymoma were markedly resistant to platinum-based agents.

Breast Cancer Susceptibility Gene

Breast Cancer Susceptibility Genes (BRCAs) involve in the repair of DSB and DNA cross-linking damage induced by DNA-damaging agents through the HR pathway (reviewed in ); BRCA1/2-deficient carcinomas have impaired HRR and become more sensitive to platinum agents. The alterations or mutations of BRCA1 and BRCA2 lead to the impaired recognition of DNA damage, and therefore depending on the patients’ BRCA status to add platinum agents into neoadjuvant therapy before surgery could receive an excellent response. However, in BRCA mutant cancers, platinum resistance still exists. To explain that phenomenon, Guillemette et al. conducted a genome-wide shRNA screen and found that loss of the nucleosome remodeling factor CHD4 might cause cisplatin resistance through a trans-lesion synthesis dependent manner rather than HRR in BRCA2 mutant cancer cells. In addition, a secondary mutation in BRCA1/2 may occur after patients receiving platinum-based chemotherapy treatment, and it restores the function of BRCA1/2, ending with platinum resistance. Researchers recently found two regulators: Wwox and deubiquitination enzyme USP13. Wwox can interact with BRCA1 and tip the DSBs repair pathway choice, and its deficiency permits significantly increased resistance to cisplatin, so it could be an efficient predictor of response to cisplatin. The knockdown of USP13 dramatically diminishes cisplatin-induced RAP80-BRCA1 foci formation, for its deficiency decreases the bind between RAP80 and K63-linked ubiquitin chain and fail the BRCA1 recruitment.

Other than ERCC and BRCA, many key components like FANCD2, PCNA, XRCC1, and RAD51, also play different roles in multiple DNA repair pathway. A better understanding of the DNA repair regulation network will provide a more accurate guide to personalized platinum-based chemotherapy.

Apoptosis

After binding to the DNA, the core downstream events platinum agents triggered is apoptosis, which is also called programmed cell death. Two main apoptosis pathways have been well proposed: the extrinsic and the intrinsic pathways. The extrinsic pathway is activated after the tumor necrosis factor family binding to the cell surface receptors of the tumor necrosis factor receptor superfamily and leads to the self-activation of initiator caspase-8. The intrinsic pathway is switched by an imbalance between proapoptotic (i.e., BAX, BAK) and antiapoptotic proteins (i.e., BCL-2, BCL-XL, BCL-w). Upon activation, proapoptotic signaling leads to mitochondrial outer membrane permeabilization, and then cytochrome c will be released, initiating a series caspase cascade. Platinum-resistant tumor cells usually have a higher threshold for apoptosis induction, mostly due to the overexpression of anti-apoptotic proteins or the defect in mitochondrial signaling. Many factors contribute to these unwanted phenomenons, such as pro-survival signal pathways [i.e., MAPK/ERK, PI3K/AKT pathway, NF-κB], and tumor microenvironment (TME) and epigenetic regulation. Researchers begin focusing on the critical role of non-coding RNA in diverse cellular processes; studies demonstrated that non-coding RNA broadly participated in proapoptotic/antiapoptotic proteins regulation and could work as therapeutic targets or predict markers. We summarized recently found apoptosis-related non-coding RNA with details listed in Table 2. Among all the contributors, we specifically concentrate on the role of p53 and TME in platinum resistance.

p53

The tumor suppressor p53 functions mainly as a transcriptional activator of many cellular programs, including checkpoint activation, DNA repair, and apoptosis, and therefore the status of p53 is crucial for the cytotoxicity of platinum agents. Downstream genes of p53 related with apoptosis include FAS, BBC3, BAX, and BIRC5. Besides the nuclear function, p53 located in cytoplasmic also promotes apoptosis through directly targeting mitochondria (reviewed in ). However, it is common to see the loss or mutation of p53 in the patients, and the disfunction of p53 will cause the failure of checkpoint response, cell cycle arrest, programmed cell death (apoptosis), and permanent cell cycle arrest (senescence). Eventually, it leads to a poor outcome of platinum-based chemotherapy. A thought-provoking work reported a nonsynonymous single-nucleotide polymorphism Pro47Ser (rs1800371) in African descent; the carriers are more tumor-prone and show a significant defect in cisplatin-induced cell death due to the impaired trans-activation ability. For this reason, more precision medicine approaches should be considered for different mutation carriers.

Antirepression, stabilization, DNA binding, and transcriptional activation are four key steps in p53’s activation along with an exquisite regulation network including phosphorylation, ubiquitination, methylation, sumoylation, neddylation, and acetylation (reviewed in ). Ubiquitinate-dependent degradation of p53 is mediated by human double minute 2 (HDM2, MDM2); therefore, interference with the HDM2/p53 pathway is an optional strategy to rescue p53 from degradation and reactivate it. Two p53-MDM2 blockers, RITA and nutlin, were discovered in 2004. Furthermore, recently Wanzel and coworkers used CRISPR-Cas9 based target validation to reveal the actual mechanisms of two p53-MDM2 blockers. Nutlin was designed to blocks the p53-binding pocket of Mdm2 and RITA was to bind the Mdm2-interacting N terminus of p53, but on the contrary, results showed that the activity of nutlin strictly depends on functional p53 while the sensitivity of RITA correlates with induction of DNA damage but not with p53. The phosphorylation status is also vital to functional p53. DACH-diacetato-dichloro-Pt(IV) (DAP) and oxaliplatin circumvent cisplatin resistance for phosphorylating p53 at Ser20 in resistant cells while cisplatin cannot, and in cisplatin-resistant MCF-7 cells, resveratrol induces serine 20 phosphorylation to activate p53 target genes such as PUMA and BAX, restoring apoptosis. All these results demonstrate that phosphorylation at Ser 20 site might be a critical event for p53 activation.

TME

The TME is a complex ecosystem and an active regulator in the progression of cancer development. The interaction between TME and cancer cells is mutual and dynamical. Tumor epithelial cells can gradually change the nature of the microenvironment, such as hypoxia, and conversely, the altered TME will regulate tumor development. TME consists of nonmalignant cells of the tumor such as cancer-associated fibroblasts (CAFs), endothelial cells and pericytes composing tumor vasculature, immune and inflammatory cells, bone marrow-derived cells, and the extracellular matrix. Some have been proven participating in the formation of drug resistance.

CAFs

The CAFs, which held the main proportion of tumor stroma, are perpetually activated, and neither revert to a normal phenotype nor undergoes apoptosis and elimination. Emerging evidence demonstrates that non-malignant CAFs can contribute to tumor proliferation, metastasis, and chemoresistance. CAFs secrete specific cytokines, proteins, or exosomal miRNA to activate certain anti-apoptosis related signaling pathways like PI3K/Akt, ANXA3/JNK, and IL-11/IL-11R/STAT3, and consequently offer tumor cells the ability of resistance. CAFs can also cause the aberrant remodeling of extracellular material and physical properties of the tumor altered, or release cysteine and GSH to limit the intracellular platinum concentration. It is worth mention that most of these researches focus on the resistance change of tumor cells after platinum treatment. However, the innate chemoresistant of CAFs is poorly understood. Qin X et al. recently reported that HNC-derived CAFs were innately resistant to cisplatin, maybe due to the high expression of ERCC1 and ERCC4.

Hypoxia

The imbalance between the rapid growth of tumor cells and inadequate supply from blood vessels alters the TME, and one of the significant characteristics is hypoxia, which is strongly associated with a poor prognosis in different cancer types, such as hepatocellular carcinoma, ovarian cancer, NSCLC, etc. Hypoxia triggers the regulation of hypoxia-inducible factor (HIF) family at the transcription level and protein level. HIFs are heterodimeric transcription factors composed of two parts: an oxygen-labile alpha subunit (HIF1α, HIF2α, or HIF3α) and a stable beta subunit (HIF1β). HIF1α and HIF2α are widely expressed in various tissues and have been well understood, yet HIF3α is less known due to its high specificity of tissue distribution and the existence of multiple variants. So only HIF1α and HIF2α will be discussed in this review. Under normoxic conditions, two specific proline residues in HIF-1α are hydroxylated by HIF prolyl hydroxylase enzymes with the cofactor oxygen, iron, ascorbate, and 2-oxoglutarate. Then, the hydroxylated HIF1α protein is bound with the von Hippel–Lindau protein, and it will recruit E3 ubiquitin ligases and put HIF1α through polyubiquitination and degradation by the 26S proteasome. Whereas under hypoxic conditions, impaired hydroxylation process stabilizes the HIF1α protein, furthermore HIF1α will translocate into nuclear and dimerize with HIF1β to transactivate the target genes which relate with glucose metabolism, angiogenesis, cell proliferation, invasion and metastasis (reviewed in; ). HIF1α has a strong association with apoptosis; it regulates apoptosis-related genes (i.e., Bcl-2, Bax, caspase 3, caspase 8), and survival signaling pathways such as NF-κB. Zheng et al. recently found that HIF-1α could activate the PI3K/AKT by up-regulating Mxd1 expression to suppress the PTEN expression. Besides, HIF accumulation facilitates the secretion of several growth factors and further activates mTOR to form a positive feedback circuit. Deactivating these signaling pathways via reducing HIFs could be a promising approach.

Highly proliferative cancer cells switch glucose flux from oxidative phosphorylation to anaerobic glycolysis, which converts pyruvate into lactate even in the presence of oxygen (the Warburg effect). This shift will quench cytosolic ROS. However, recent evidence shows that in some cytotoxic antineoplastic drug-resistance tumor cells, aerobic glycolysis can shift back to oxidative phosphorylation. HIFs act as inducers to aerobic glycolysis and a suppressor to mitochondrial function; it can regulate many main enzymes in glycolysis and tricarboxylic acid cycle like GLUT1, LDH-A, PDH, and PDK1. Downregulating HIF-1α to redirect the aerobic glycolysis towards oxidative phosphorylation resulting in overexpressing ROS can resensitize the cisplatin-resistance ovarian cancer cells. ROS act as a double-bladed sword in the platinum treatment. On the one hand, platinum agents-induced cytotoxicity is strongly linked to excessed ROS generation. Unlike cisplatin, oxaliplatin prefers to stimulate O2– production rather than H2O2. Some essential components were newly discovered. Wang et al. reported that Scribble promotes cisplatin-induced apoptosis via protecting Nox2/ROS. Inositol 1, 3, 4, 5-tetrakisphosphate, the product of inositol-trisphosphate 3-kinase B, inhibits NADPH oxidase 4, thereby inhibiting the generation of cisplatin-induced ROS. The imbalance between ROS production and elimination is often seen in resistance cells. Besides GSH and MTs, the elevated oxidative branch of the pentose phosphate pathway is another strong defensor against ROS. The key, it seems, is whether the ROS level can reach the threshold to trigger cell death. Stimulating the production or blocking the neutralization of ROS might be a promising way to reverse platinum resistance. On the other hand, the increased ROS level in cancer cells might accelerates the development of tumor aggressiveness and drug resistance. Increased ROS can activate cellular survival pathways including c-Myc–miR-137–EZH2 pathway, IL-11–JAK2–STAT5 pathway, ATR–Chk1 pathway and AXL et al. ROS may also mediate metabolism reprogramming.

Classical strategies include direct/indirect HIF targeting and interference in upstream/downstream HIF regulators/signaling pathways. Many prodrugs, specific HIF inhibitors, and non-selective inhibitors are developed to inhibit HIFs with many different mechanisms including inhibition of HIF dimerization, mRNA or protein expression, transcriptional activity, and DNA binding capacity (reviewed in ). Recently found Trx-1 and KLF5 are upstream regulators of HIF 1α. Trx-1 increase the expression and the binding capacity of HIF1α through enhanced interaction with Ref-1 and inhibition of Trx-1/Ref-1 axis can strengthen the oxidative phosphorylation, and reverse the resistance to cisplatin. Gong et al. reported KLF5 knockdown suppressed hypoxia-induced cisplatin resistance by inhibiting HIF1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway. Non-coding RNAs can also increase the expression of HIF1α, resulting in platinum resistance.

Besides HIF1α, HIF2α also associate with platinum response. GBM cells show an increase in cisplatin resistance after exposure to hypoxia, and downregulating HIF2α, not HIF1α, significantly sensitizes U251 and U87 cells (GBM cell lines) to cisplatin. Knocking down HIF2a significantly increases the sensitivity to cisplatin in A549 cells.

Autophagy

Autophagy, a “self-digestion” process, occurs in all eukaryotes. It is essential for nutrient regulation and intracellular quality control and homeostasis. Also, autophagy functions as a self-defense strategy by recycling macromolecules as an alternative energy source. However, if autophagy continuously or excessively proceeds, cell death will be triggered. There are generally three major types of autophagy, macroautophagy, microautophagy, and chaperone-mediated autophagy. In this review, only macroautophagy (referred to as autophagy) will be discussed. Macroautophagy seems to have a conflicting role in tumorigenesis and progression. It can act as a prodeath or prosurvival role at different cancer stages (reviewed in ). After platinum treatment, the increased drug-induced autophagy is observed in platinum-resistant cells, along with the increased basal autophagy. Inhibition of autophagy via autophagy inhibitor or interference in regulatory elements or noncoding RNAs has been proven can reduce the platinum resistance. Using 3-methyladenine or chloroquine to inhibit early/later-stage autophagy can both enhance platinum-mediated cytotoxicity. Autophagy is highly controlled by regulatory elements including PI3K–Akt–mTOR pathway, Beclin1, Bcl-2, Ras, p53, and noncoding RNAs [long non-coding RNAs (LncRNs) and miRNAs] (reviewed in ). Recently, new regulators dual-specificity protein phosphatase 1 (DUSP1), heparinase, and HMGB1, GFRA1 are reported. Targeting these regulatory elements can restore the efficiency of platinum agents. LncRNAs and miRNAs affect the platinum resistance by targeting key components like ATG7 or signaling pathways like PI3K/AKT/mTOR in autophagy. We summarized recently found autophagy-related non-coding RNA with details listed in Table 2.

Another big issue caused by autophagy is related to cancer stem cells (CSC). CSCs are a subpopulation of cancer cells within the tumor that have the ability to self-renew and to differentiate. CSCs have long been considered as the main culprit for drug resistance and relapse. Growing evidence indicated that autophagy protects CSCs for participating in the regulation of stem cell differentiation, somatic reprogramming and self-renewal capacity. Yang et al. reported that oxaliplatin-induced autophagy enriches the population of colorectal CD44+ CSCs and maintain the stemness of colorectal CSCs, this protection eventually causes chemoresistance in colorectal CSCs, and so did Nail’s group. They found that autophagy regulates the expression of stemness surface marker CD44, drug resistance marker ABCB1 and invasion mediator ADAM17 to help maintain stemness and chemoresistance, but the mechanism remains unclear. Targeting autophagy to diminish the CSCs subpopulation might be a new direction to overcome platinum resistance.

In most aforementioned cases, increased autophagy has a negative relation to platinum response. However, some phytochemicals show anti-resistance effects via inducing autophagy. Zhu et al. reported that hyperoside sensitizes ovarian cancer cells to cisplatin relay on PGRMC1-dependent autophagy; resveratrol can induce autophagy and apoptosis in cisplatin-resistant human oral cancer.

Further investigation about the changeful role of autophagy in tumor development and the complex regulatory mechanism involved in will provide more potential intervention targets and approaches for how and when to overcome platinum resistance.

Conclusions

The resistance of platinum agents is still an ordeal. Elucidating the molecular mechanisms underlying the resistance phenomena will largely extend the clinic application of platinum agents. The main mechanisms are summarized as changed cellular platinum accumulation, increased detoxification system, increased DNA repair, decreased apoptosis, and autophagy. As the relative technologies develop rapidly, new research means such as CRISPR-Cas9, RNAi-based functional genetic screening help researchers to reexamine some key regulators and illuminate their actual impact on platinum resistance. Another notable tendency is the deeper understanding of the epigenetic modification. Non-coding RNA shows extremely complicated regulation functions on all sides and the potential to be predictive markers. The intercrossed application among genome, epigenome, transcriptome, proteome, and metabolome systems will provide a new aspect to break through the bottlenecks. But the challenges still remain as to how to utilize the emerged candidate targets as predictive markers to assign patients to more promising therapy or as therapeutic targets to improve the curative effect of platinum-based antitumor agents.

Author Contributions

JZ, LC, and HW searched for articles, and JZ wrote the first draft of the review. JL made the figures. YK and LY revised the whole manuscript. SZ and LY supervised the process. All authors approved the submission of this manuscript.

Funding

This work was supported by the Leading Talent of "Ten Thousand Plan" - National High-Level Talents Special Support Plan and the grants from National Natural Science Foundation of China (81773805 and 81703616)

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 246

  1. 1.

    Aguilar A. (2016 ). Kidney cancer: OCT2 demethylation cracks open oxaliplatin resistance. Nat. Rev. Nephrol. 12 (10), 581.

    Not in our library10.1038/nrneph.2016.122 (opens in a new tab)

  2. 2.
    Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary · 2010
    No notice
  3. 3.

    Ahmed E. M. Bandopadhyay G. Coyle B. Grabowska A. (2018 ). A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells. Cell Oncol. (Dordr.) 41 (3), 319–328.

    Not in our library10.1007/s13402-018-0374-8 (opens in a new tab)

  4. 4.

    Ai Z. Lu Y. Qiu S. Fan Z. (2016 ). Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Lett. 373 (1), 36–44.

    Not in our library10.1016/j.canlet.2016.01.009 (opens in a new tab)

  5. 5.

    Akerfeldt M. C. Tran C. M. Shen C. Hambley T. W. New E. J. (2017 ). Interactions of cisplatin and the copper transporter CTR1 in human colon cancer cells. J. Biol. Inorg. Chem. 22 (5), 765–774.

    Not in our library10.1007/s00775-017-1467-y (opens in a new tab)

  6. 6.

    Akkari L. Joyce J. A. (2016 ). Microenvironmental InterFereNce of metabolism regulates chemosensitivity. Cell Res. 26 (8), 867–868.

    Not in our library10.1038/cr.2016.82 (opens in a new tab)

  7. 7.

    Al-Eisawi Z. Beale P. Chan C. Yu J. Q. Huq F. (2013 ). Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models. J. Ovarian Res. 6 (1), 78.

    Not in our library10.1186/1757-2215-6-78 (opens in a new tab)

  8. 8.

    Al-Minawi A. Z. Lee Y. F. Hakansson D. Johansson F. Lundin C. Saleh-Gohari N. (2009 ). The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cross-links. Nucleic Acids Res. 37 (19), 6400–6413.

    Not in our library10.1093/nar/gkp705 (opens in a new tab)

  9. 9.
    Impaired Glutathione Synthesis in Neurodegeneration · 2013
    No notice
  10. 10.

    Arora S. Kothandapani A. Tillison K. Kalman-Maltese V. Patrick S. M. (2010 ). Downregulation of XPF–ERCC1 enhances cisplatin efficacy in cancer cells☆. DNA Repair 9 (7), 745–753.

    Not in our library10.1016/j.dnarep.2010.03.010 (opens in a new tab)

  11. 11.

    Bai L. Wang S. (2014 ). Targeting apoptosis pathways for new cancer therapeutics. Annu. Rev. Med. 65, 139–155.

    Not in our library10.1146/annurev-med-010713-141310 (opens in a new tab)

  12. 12.

    Bao L. Wu J. Dodson M. Rojo de la Vega,. E. M. Ning Y. Zhang Z. (2017 ). ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells. Mol. Carcinog. 56 (6), 1543–1553.

    Not in our library10.1002/mc.22615 (opens in a new tab)

  13. 13.

    Basu S. Barnoud T. Kung C. P. Reiss M. Murphy M. E. (2016 ). The African-specific S47 polymorphism of p53 alters chemosensitivity. Cell Cycle 15 (19), 2557–2560.

    Not in our library10.1080/15384101.2016.1215390 (opens in a new tab)

  14. 14.

    Belli C. Trapani D. Viale G. D’Amico P. Duso B. A. Della Vigna P. (2018 ). Targeting the microenvironment in solid tumors. Cancer Treat Rev. 65, 22–32.

    Not in our library10.1016/j.ctrv.2018.02.004 (opens in a new tab)

  15. 15.

    Benard A. Janssen C. M. van den Elsen P. J. van Eggermond M. C. Hoon D. S. van de Velde C. J. (2014 ). Chromatin status of apoptosis genes correlates with sensitivity to chemo-, immune- and radiation therapy in colorectal cancer cell lines. Apoptosis 19 (12), 1769–1778.

    Not in our library10.1007/s10495-014-1042-8 (opens in a new tab)

  16. 16.

    Beretta G. L. Benedetti V. Cossa G. Assaraf Y. G. Bram E. Gatti L. (2010 ). Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem. Pharmacol. 79 (8), 1108–1117.

    Not in our library10.1016/j.bcp.2009.12.002 (opens in a new tab)

  17. 17.

    Bertout J. A. Patel S. A. Simon M. C. (2008 ). The impact of O2 availability on human cancer. Nat. Rev. Cancer 8 (12), 967–975.

    Not in our library10.1038/nrc2540 (opens in a new tab)

  18. 18.

    Blair B. G. Larson C. A. Safaei R. Howell S. B. (2009 ). Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin. Cancer Res. 15 (13), 4312–4321.

    Not in our library10.1158/1078-0432.ccr-09-0311 (opens in a new tab)

  19. 19.

    Blair B. G. Larson C. A. Adams P. L. Abada P. B. Pesce C. E. Safaei R. (2011 ). Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol. Pharmacol. 79 (1), 157–166.

    Not in our library10.1124/mol.110.068411 (opens in a new tab)

  20. 20.

    Boal A. K. Rosenzweig A. C. (2009 ). Crystal structures of cisplatin bound to a human copper chaperone. J. Am. Chem. Soc. 131 (40), 14196–14197.

    Not in our library10.1021/ja906363t (opens in a new tab)

  21. 21.

    Bompiani K. M. Tsai C. Y. Achatz F. P. Liebig J. K. Howell S. B. (2016 ). Copper transporters and chaperones CTR1, CTR2, ATOX1, and CCS as determinants of cisplatin sensitivity. Metallomics 8 (9), 951–962.

    Not in our library10.1039/c6mt00076b (opens in a new tab)

  22. 22.

    Borst P. Evers R. Kool M. Wijnholds J. (2000 ). A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92 (16), 1295–1302.

    Not in our library10.1093/jnci/92.16.1295 (opens in a new tab)

  23. 23.

    Brozovic A. Ambriovic-Ristov A. Osmak M. (2010 ). The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin. Crit. Rev. Toxicol. 40 (4), 347–359.

    Not in our library10.3109/10408441003601836 (opens in a new tab)

  24. 24.

    Brozovic A. Vukovic L. Polancac D. S. Arany I. Koberle B. Fritz G. (2013 ). Endoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to Carboplatin but is absent in Carboplatin-resistant cells. PloS One 8 (9), e76397.

    Not in our library10.1371/journal.pone.0076397 (opens in a new tab)

  25. 25.

    Bruno P. M. Liu Y. Park G. Y. Murai J. Koch C. E. Eisen T. J. (2017 ). A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat. Med. 23 (4), 461–471.

    Not in our library10.1038/nm.4291 (opens in a new tab)

  26. 26.

    Burger H. Zoumaro-Djayoon A. Boersma A. W. Helleman J. Berns E. M. Mathijssen R. H. (2010 ). Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br. J. Pharmacol. 159 (4), 898–908.

    Not in our library10.1111/j.1476-5381.2009.00569.x (opens in a new tab)

  27. 27.

    Buss I. Hamacher A. Sarin N. Kassack M. U. Kalayda G. V. (2018 ). Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics 10 (3), 414–425.

    Not in our library10.1039/c7mt00334j (opens in a new tab)

  28. 28.

    Byun S. S. Kim S. W. Choi H. Lee C. Lee E. (2005 ). Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities. BJU Int. 95 (7), 1086–1090.

    Not in our library10.1111/j.1464-410x.2005.05472.x (opens in a new tab)

  29. 29.

    Cadoni E. Valletta E. Caddeo G. Isaia F. Cabiddu M. G. Vascellari S. (2017 ). Competitive reactions among glutathione, cisplatin and copper-phenanthroline complexes. J. Inorg. Biochem. 173, 126–133.

    Not in our library10.1016/j.jinorgbio.2017.05.004 (opens in a new tab)

  30. 30.

    Chaney S. G. Campbell S. L. Bassett E. Wu Y. (2005 ). Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit. Rev. Oncol. Hematol. 53 (1), 3–11.

    Not in our library10.1016/j.critrevonc.2004.08.008 (opens in a new tab)

  31. 31.

    Chang C. H. Lee C. Y. Lu C. C. Tsai F. J. Hsu Y. M. Tsao J. W. (2017 ). Resveratrol-induced autophagy and apoptosis in cisplatin-resistant human oral cancer CAR cells: A key role of AMPK and Akt/mTOR signaling. Int. J. Oncol. 50 (3), 873–882.

    Not in our library10.3892/ijo.2017.3866 (opens in a new tab)

  32. 32.

    Chapman T. M. Gillen K. J. Wallace C. Lee M. T. Bakrania P. Khurana P. (2015 ). Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF. Bioorg. Med. Chem. Lett. 25 (19), 4097–4103.

    Not in our library10.1016/j.bmcl.2015.08.031 (opens in a new tab)

  33. 33.
    Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy · 2010
    No notice
  34. 34.

    Chen X. Zhang Y. Shi Y. Lian H. Tu H. Han S. (2015 ). MiR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2. Int. J. Oncol. 47 (4), 1603–1611.

    Not in our library10.3892/ijo.2015.3143 (opens in a new tab)

  35. 35.

    Chen X. Jiang Y. Huang Z. Li D. Chen X. Cao M. (2016 ). miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin. Sci. Rep. 6, 19455.

    Not in our library10.1038/srep19455 (opens in a new tab)

  36. 36.

    Chen J. Solomides C. Simpkins F. Simpkins H. (2017 ). The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy. Cancer Chemother. Pharmacol. 79 (2), 369–380.

    Not in our library10.1007/s00280-016-3225-1 (opens in a new tab)

  37. 37.

    Chen Y. Cao X. Y. Li Y. N. Qiu Y. Y. Li Y. N. Li W. (2018 ). Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer. Am. J. Physiol. Cell Physiol. 315 (2), C225–C235.

    Not in our library10.1152/ajpcell.00283.2017 (opens in a new tab)

  38. 38.

    Cheng C. Qin Y. Zhi Q. Wang J. Qin C. (2018 ). Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/beta-catenin signaling pathways by up-regulating miR-34a. Int. J. Biol. Macromol. 107 (Pt B), 2620–2629.

    Not in our library10.1016/j.ijbiomac.2017.10.154 (opens in a new tab)

  39. 39.

    Chisholm C. L. Wang H. Wong A. H. Vazquez-Ortiz G. Chen W. Xu X. (2016 ). Ammonium tetrathiomolybdate treatment targets the copper transporter ATP7A and enhances sensitivity of breast cancer to cisplatin. Oncotarget 7 (51), 84439–84452.

    Not in our library10.18632/oncotarget.12992 (opens in a new tab)

  40. 40.
    Mechanism of Cisplatin-Induced Cytotoxicity Is Correlated to Impaired Metabolism Due to Mitochondrial ROS Generation · 2015
    No notice
  41. 41.

    Cirilo P. D. R. de Sousa Andrade L. N. Correa B. R. S. Qiao M. Furuya T. K. Chammas R. (2017 ). MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1. BMC Cancer 17 (1), 750.

    Not in our library10.1186/s12885-017-3721-7 (opens in a new tab)

  42. 42.

    Cruz-Bermudez A. Laza-Briviesca R. Vicente-Blanco R. J. Garcia-Grande A. Coronado M. J. Laine-Menendez S. (2019 ). Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1alpha in NSCLC which can be overcome by OXPHOS inhibition. Free Radic. Biol. Med. 135, 167–181.

    Not in our library10.1016/j.freeradbiomed.2019.03.009 (opens in a new tab)

  43. 43.

    Dai C. X. Gao Q. Qiu S. J. Ju M. J. Cai M. Y. Xu Y. F. (2009 ). Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer 9, 418.

    Not in our library10.1186/1471-2407-9-418 (opens in a new tab)

  44. 44.

    Dalby K. N. Tekedereli I. Lopez-Berestein G. Ozpolat B. (2010 ). Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 6 (3), 322–329.

    Not in our library10.4161/auto.6.3.11625 (opens in a new tab)

  45. 45.

    Danford A. J. Wang D. Wang Q. Tullius T. D. Lippard S. J. (2005 ). Platinum anticancer drug damage enforces a particular rotational setting of DNA in nucleosomes. Proc. Natl. Acad. Sci. U. S. A 102 (35), 12311–12316.

    Not in our library10.1073/pnas.0506025102 (opens in a new tab)

  46. 46.

    Dann R. B. DeLoia J. A. Timms K. M. Zorn K. K. Potter J. Flake D. D. 2nd (2012 ). BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol. Oncol. 125 (3), 677–682.

    Not in our library10.1016/j.ygyno.2012.03.006 (opens in a new tab)

  47. 47.

    Dijt F. J. Fichtinger-Schepman A. M. Berends F. Reedijk J. (1988 ). Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res. 48 (21), 6058–6062.

    Not in our library

  48. 48.

    Drayton R. M. Dudziec E. Peter S. Bertz S. Hartmann A. Bryant H. E. (2014 ). Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin. Cancer Res. 20 (7), 1990–2000.

    Not in our library10.1158/1078-0432.ccr-13-2805 (opens in a new tab)

  49. 49.

    Duan C. (2016 ). Hypoxia-inducible factor 3 biology: complexities and emerging themes. Am. J. Physiol. Cell Physiol. 310 (4), C260–C269.

    Not in our library10.1152/ajpcell.00315.2015 (opens in a new tab)

  50. 50.

    Estrela J. M. Ortega A. Obrador E. (2006 ). Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 43 (2), 143–181.

    Not in our library10.1080/10408360500523878 (opens in a new tab)

  51. 51.

    Faivre S. Chan D. Salinas R. Woynarowska B. Woynarowski J. M. (2003 ). DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem. Pharmacol. 66 (2), 225–237.

    Not in our library10.1016/s0006-2952(03)00260-0 (opens in a new tab)

  52. 52.
    LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR‐184 expression · 2017
    No notice
  53. 53.

    Fang T. Chen W. Sheng Y. Yuan S. Tang Q. Li G. (2019 ). Tetrathiomolybdate induces dimerization of the metal-binding domain of ATPase and inhibits platination of the protein. Nat. Commun. 10 (1), 186.

    Not in our library10.1038/s41467-018-08102-z (opens in a new tab)

  54. 54.

    Foulkes W. D. Shuen A. Y. (2013 ). In brief: BRCA1 and BRCA2. J. Pathol. 230 (4), 347–349.

    Not in our library10.1002/path.4205 (opens in a new tab)

  55. 55.

    Fu S. Naing A. Fu C. Kuo M. T. Kurzrock R. (2012 ). Overcoming platinum resistance through the use of a copper-lowering agent. Mol. Cancer Ther. 11 (6), 1221–1225.

    Not in our library10.1158/1535-7163.mct-11-0864 (opens in a new tab)

  56. 56.

    Fu Q. Cheng J. Zhang J. Zhang Y. Chen X. Xie J. (2016 ). Downregulation of YEATS4 by miR-218 sensitizes colorectal cancer cells to L-OHP-induced cell apoptosis by inhibiting cytoprotective autophagy. Oncol. Rep. 36 (6), 3682–3690.

    Not in our library10.3892/or.2016.5195 (opens in a new tab)

  57. 57.

    Fujiwara N. Inoue J. Kawano T. Tanimoto K. Kozaki K. Inazawa J. (2015 ). miR-634 Activates the Mitochondrial Apoptosis Pathway and Enhances Chemotherapy-Induced Cytotoxicity. Cancer Res. 75 (18), 3890–3901.

    Not in our library10.1158/0008-5472.can-15-0257 (opens in a new tab)

  58. 58.

    Fukuda T. Oda K. Wada-Hiraike O. Sone K. Inaba K. Ikeda Y. (2015 ). The anti-malarial chloroquine suppresses proliferation and overcomes cisplatin resistance of endometrial cancer cells via autophagy inhibition. Gynecol. Oncol. 137 (3), 538–545.

    Not in our library10.1016/j.ygyno.2015.03.053 (opens in a new tab)

  59. 59.

    Gadhikar M. A. Sciuto M. R. Alves M. V. Pickering C. R. Osman A. A. Neskey D. M. (2013 ). Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol. Cancer Ther. 12 (9), 1860–1873.

    Not in our library10.1158/1535-7163.mct-13-0157 (opens in a new tab)

  60. 60.

    Gao J. Wang W. (2019 ). Knockdown of galectin-1 facilitated cisplatin sensitivity by inhibiting autophagy in neuroblastoma cells. Chem. Biol. Interact. 297, 50–56.

    Not in our library10.1016/j.cbi.2018.10.014 (opens in a new tab)

  61. 61.

    Gao Z. J. Yuan W. D. Yuan J. Q. Yuan K. Wang Y. (2018 ). Downregulation of HIF-2alpha Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin. Med. Sci. Monit. 24, 1104–1111.

    Not in our library10.12659/msm.906107 (opens in a new tab)

  62. 62.

    Gao H. Zhang S. Hu T. Qu X. Zhai J. Zhang Y. (2019 ). Omeprazole protects against cisplatin-induced nephrotoxicity by alleviating oxidative stress, inflammation, and transporter-mediated cisplatin accumulation in rats and HK-2cells. Chem. Biol. Interact. 297, 130–140.

    Not in our library10.1016/j.cbi.2018.11.008 (opens in a new tab)

  63. 63.
    Cellular accumulation of the anticancer agent cisplatin: A review · 1993
    No notice
  64. 64.

    Gillet L. C. Scharer O. D. (2006 ). Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem. Rev. 106 (2), 253–276.

    Not in our library10.1021/cr040483f (opens in a new tab)

  65. 65.

    Golan T. Kanji Z. S. Epelbaum R. Devaud N. Dagan E. Holter S. (2014 ). Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br. J. Cancer 111 (6), 1132–1138.

    Not in our library10.1038/bjc.2014.418 (opens in a new tab)

  66. 66.

    Gong T. Cui L. Wang H. Wang H. Han N. (2018 ). Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1alpha-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway. J. Transl. Med. 16 (1), 164.

    Not in our library10.1186/s12967-018-1543-2 (opens in a new tab)

  67. 67.

    Goodspeed A. Jean A. Costello J. C. (2019 ). A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. Eur. Urol. 75 (2), 242–250.

    Not in our library10.1016/j.eururo.2018.10.040 (opens in a new tab)

  68. 68.

    Graf N. Ang W. H. Zhu G. Myint M. Lippard S. J. (2011 ). Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity. Chembiochem 12 (7), 1115–1123.

    Not in our library10.1002/cbic.201000724 (opens in a new tab)

  69. 69.

    Guillemette S. Serra R. W. Peng M. Hayes J. A. Konstantinopoulos P. A. Green M. R. (2015 ). Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4. Genes Dev. 29 (5), 489–494.

    Not in our library10.1101/gad.256214.114 (opens in a new tab)

  70. 70.

    Gupta A. Lutsenko S. (2009 ). Human copper transporters: mechanism, role in human diseases and therapeutic potential. Future Med. Chem. 1 (6), 1125–1142.

    Not in our library10.4155/fmc.09.84 (opens in a new tab)

  71. 71.

    Habel N. Hamidouche Z. Girault I. Patino-Garcia A. Lecanda F. Marie P. J. (2013 ). Zinc chelation: a metallothionein 2A’s mechanism of action involved in osteosarcoma cell death and chemotherapy resistance. Cell Death Dis. 4, e874.

    Not in our library10.1038/cddis.2013.405 (opens in a new tab)

  72. 72.

    Hall M. D. Okabe M. Shen D.-W. Liang X.-J. Gottesman M. M. (2008 ). The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy. Annu. Rev. Pharmacol. Toxicol. 48 (1), 495–535.

    Not in our library10.1146/annurev.pharmtox.48.080907.180426 (opens in a new tab)

  73. 73.

    Hernandez-Luna M. A. Rocha-Zavaleta L. Vega M. I. Huerta-Yepez S. (2013 ). Hypoxia inducible factor-1alpha induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-xL. Leuk. Lymphoma 54 (5), 1048–1055.

    Not in our library10.3109/10428194.2012.733874 (opens in a new tab)

  74. 74.

    Hernandez-Valencia J. Garcia-Villa E. Arenas-Hernandez A. Garcia-Mena J. Diaz-Chavez J. Gariglio P. (2018 ). Induction of p53 phosphorylation at serine 20 by resveratrol is required to activate p53 target genes, restoring apoptosis in MCF-7 cells resistant to cisplatin. Nutrients 10 (9), 1148.

    Not in our library10.3390/nu10091148 (opens in a new tab)

  75. 75.

    Hervouet E. Simonnet H. Godinot C. (2007 ). Mitochondria and reactive oxygen species in renal cancer. Biochimie 89 (9), 1080–1088.

    Not in our library10.1016/j.biochi.2007.03.010 (opens in a new tab)

  76. 76.

    Holzer A. K. Howell S. B. (2006 ). The Internalization and Degradation of Human Copper Transporter 1 following Cisplatin Exposure. Cancer Res. 66 (22), 10944–10952.

    Not in our library10.1158/0008-5472.can-06-1710 (opens in a new tab)

  77. 77.

    Holzer A. K. Manorek G. H. Howell S. B. (2006 ). Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol. Pharmacol. 70 (4), 1390–1394.

    Not in our library10.1124/mol.106.022624 (opens in a new tab)

  78. 78.

    Howell S. B. Safaei R. Larson C. A. Sailor M. J. (2010 ). Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs. Mol. Pharmacol. 77 (6), 887–894.

    Not in our library10.1124/mol.109.063172 (opens in a new tab)

  79. 79.

    Huang C. P. Fofana M. Chan J. Chang C. J. Howell S. B. (2014 ). Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. Metallomics 6 (3), 654–661.

    Not in our library10.1039/c3mt00331k (opens in a new tab)

  80. 80.

    Huang H. Tang J. Zhang L. Bu Y. Zhang X. (2018 ). miR-874 regulates multiple-drug resistance in gastric cancer by targeting ATG16L1. Int. J. Oncol. 53 (6), 2769–2779.

    Not in our library10.3892/ijo.2018.4593 (opens in a new tab)

  81. 81.

    Huang F. X. Chen H. J. Zheng F. X. Gao Z. Y. Sun P. F. Peng Q. (2019 ). LncRNA BLACAT1 is involved in chemoresistance of nonsmall cell lung cancer cells by regulating autophagy. Int. J. Oncol. 54 (1), 339–347.

    Not in our library10.3892/ijo.2018.4614 (opens in a new tab)

  82. 82.

    Hung J. J. Yang M. H. Hsu H. S. Hsu W. H. Liu J. S. Wu K. J. (2009 ). Prognostic significance of hypoxia-inducible factor-1alpha, TWIST1 and Snail expression in resectable non-small cell lung cancer. Thorax 64 (12), 1082–1089.

    Not in our library10.1136/thx.2009.115691 (opens in a new tab)

  83. 83.

    Ishida S. Lee J. Thiele D. J. Herskowitz I. (2002 ). Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. U. S. A 99 (22), 14298–14302.

    Not in our library10.1073/pnas.162491399 (opens in a new tab)

  84. 84.

    Ishida S. McCormick F. Smith-McCune K. Hanahan D. (2010 ). Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 17 (6), 574–583.

    Not in our library10.1016/j.ccr.2010.04.011 (opens in a new tab)

  85. 85.

    Ishikawa T. Ali-Osman F. (1993 ). Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J. Biol. Chem. 268 (27), 20116–20125.

    Not in our library

  86. 86.

    Issaeva N. Bozko P. Enge M. Protopopova M. Verhoef L. G. Masucci M. (2004 ). Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10 (12), 1321–1328.

    Not in our library10.1038/nm1146 (opens in a new tab)

  87. 87.

    Jamieson E. R. Lippard S. J. (1999 ). Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem. Rev. 99 (9), 2467–2498.

    Not in our library10.1021/cr980421n (opens in a new tab)

  88. 88.

    Jedlitschky G. Leier I. Buchholz U. Center M. Keppler D. (1994 ). ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res. 54 (18), 4833–4836.

    Not in our library

  89. 89.

    Jennis M. Kung C. P. Basu S. Budina-Kolomets A. Leu J. I. Khaku S. (2016 ). An African-specific polymorphism in the TP53 gene impairs p53 tumor suppressor function in a mouse model. Genes Dev. 30 (8), 918–930.

    Not in our library10.1101/gad.275891.115 (opens in a new tab)

  90. 90.

    Jiang L. Zhang Q. Ren H. Ma S. Lu C. Liu B. (2015 ). Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells. PloS One 10 (4), e0124994.

    Not in our library10.1371/journal.pone.0124994 (opens in a new tab)

  91. 91.

    Jung Y. Lippard S. J. (2007 ). Direct cellular responses to platinum-induced DNA damage. Chem. Rev. 107 (5), 1387–1407.

    Not in our library10.1021/cr068207j (opens in a new tab)

  92. 92.

    Kalayda G. V. Wagner C. H. Buß I. Reedijk J. Jaehde U. (2008 ). Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer 8 (1), 175.

    Not in our library10.1186/1471-2407-8-175 (opens in a new tab)

  93. 93.

    Kartalou M. Essigmann J. M. (2001 ). Recognition of cisplatin adducts by cellular proteins. Mutat. Res. 478 (1-2), 1–21.

    Not in our library10.1016/s0027-5107(01)00142-7 (opens in a new tab)

  94. 94.

    Keppler D. (2011 ). Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb. Exp. Pharmacol. 201, 299–323.

    Not in our library10.1007/978-3-642-14541-4_8 (opens in a new tab)

  95. 95.

    Kim R. Tanabe K. Uchida Y. Emi M. Inoue H. Toge T. (2002 ). Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother. Pharmacol. 50 (5), 343–352.

    Not in our library10.1007/s00280-002-0522-7 (opens in a new tab)

  96. 96.

    Kim E. S. Tang X. Peterson D. R. Kilari D. Chow C. W. Fujimoto J. (2014 ). Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer 85 (1), 88–93.

    Not in our library10.1016/j.lungcan.2014.04.005 (opens in a new tab)

  97. 97.

    Kim E. A. Kim T. G. Sung E. G. Song I. H. Kim J. Y. Doh K. O. (2017 a). miR-148a increases the sensitivity to cisplatin by targeting Rab14 in renal cancer cells. Int. J. Oncol. 50 (3), 984–992.

    Not in our library10.3892/ijo.2017.3851 (opens in a new tab)

  98. 98.

    Kim M. Jung J. Y. Choi S. Lee H. Morales L. D. Koh J. T. (2017 b). GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy. Autophagy 13 (1), 149–168.

    Not in our library10.1080/15548627.2016.1239676 (opens in a new tab)

  99. 99.
    The Functions of Metallothionein and ZIP and ZnT Transporters: An Overview and Perspective · 2016
    No notice
  100. 100.

    Kong L. R. Chua K. N. Sim W. J. Ng H. C. Bi C. Ho J. (2015 ). MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma. Mol. Cancer Ther. 14 (7), 1750–1760.

    Not in our library10.1158/1535-7163.mct-15-0062 (opens in a new tab)

  101. 101.

    Krizkova S. Fabrik I. Huska D. Adam V. Babula P. Hrabeta J. (2010 ). An adsorptive transfer technique coupled with brdicka reaction to reveal the importance of metallothionein in chemotherapy with platinum based cytostatics. Int. J. Mol. Sci. 11 (12), 4826–4842.

    Not in our library10.3390/ijms11124826 (opens in a new tab)

  102. 102.

    Kruse J. P. Gu W. (2009 ). Modes of p53 regulation. Cell 137 (4), 609–622.

    Not in our library10.1016/j.cell.2009.04.050 (opens in a new tab)

  103. 103.

    Kumar B. Koul S. Khandrika L. Meacham R. B. Koul H. K. (2008 ). Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 68 (6), 1777–1785.

    Not in our library10.1158/0008-5472.can-07-5259 (opens in a new tab)

  104. 104.

    Kumar A. Singh U. K. Chaudhary A. (2015 ). Targeting autophagy to overcome drug resistance in cancer therapy. Future Med. Chem. 7 (12), 1535–1542.

    Not in our library10.4155/fmc.15.88 (opens in a new tab)

  105. 105.

    Kuwahara A. Yamamori M. Nishiguchi K. Okuno T. Chayahara N. Miki I. (2009 ). Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma. Int. J. Med. Sci. 6 (6), 305–311.

    Not in our library10.7150/ijms.6.305 (opens in a new tab)

  106. 106.

    Lee J. H. Chae J. W. Kim J. K. Kim H. J. Chung J. Y. Kim Y. H. (2015 ). Inhibition of cisplatin-resistance by RNA interference targeting metallothionein using reducible oligo-peptoplex. J. Control Release 215, 82–90.

    Not in our library10.1016/j.jconrel.2015.07.015 (opens in a new tab)

  107. 107.

    Lehmann J. Seebode C. Smolorz S. Schubert S. Emmert S. (2017 ). XPF knockout via CRISPR/Cas9 reveals that ERCC1 is retained in the cytoplasm without its heterodimer partner XPF. Cell Mol. Life Sci. 74 (11), 2081–2094.

    Not in our library10.1007/s00018-017-2455-7 (opens in a new tab)

  108. 108.

    Li Q. Yu J. J. Mu C. Yunmbam M. K. Slavsky D. Cross C. L. (2000 ). Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res. 20 (2a), 645–652.

    Not in our library

  109. 109.

    Li H. Fan X. Houghton J. (2007 ). Tumor microenvironment: the role of the tumor stroma in cancer. J. Cell Biochem. 101 (4), 805–815.

    Not in our library10.1002/jcb.21159 (opens in a new tab)

  110. 110.

    Li X. He Y. Xu Y. Huang X. Liu J. Xie M. (2016 a). KLF5 mediates vascular remodeling via HIF-1alpha in hypoxic pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 310 (4), L299–L310.

    Not in our library10.1152/ajplung.00189.2015 (opens in a new tab)

  111. 111.

    Li X. Lin Z. Zhang B. Guo L. Liu S. Li H. (2016 b). beta-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1. Sci. Rep. 6, 21010.

    Not in our library10.1038/srep21010 (opens in a new tab)

  112. 112.

    Li Y. Liu B. Yang F. Yu Y. Zeng A. Ye T. (2016 c). Lobaplatin induces BGC-823 human gastric carcinoma cell apoptosis via ROS- mitochondrial apoptotic pathway and impairs cell migration and invasion. BioMed. Pharmacother. 83, 1239–1246.

    Not in our library10.1016/j.biopha.2016.08.053 (opens in a new tab)

  113. 113.

    Li B. Wang W. Li Z. Chen Z. Zhi X. Xu J. (2017 a). MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression. Cancer Lett. 410, 212–227.

    Not in our library10.1016/j.canlet.2017.09.035 (opens in a new tab)

  114. 114.
    USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response · 2017
    Not checked
  115. 115.

    Li Y. Zeng J. Huang M. An J. Bai P. Wu L. (2017 c). A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma. Cancer 123 (3), 420–425.

    Not in our library10.1002/cncr.30328 (opens in a new tab)

  116. 116.

    Liang L. Zhang Z. Qin X. Gao Y. Zhao P. Liu J. (2018 ). Gambogic Acid Inhibits Melanoma through Regulation of miR-199a-3p/ZEB1 Signalling. Basic Clin. Pharmacol. Toxicol. 123 (6), 692–703.

    Not in our library10.1111/bcpt.13090 (opens in a new tab)

  117. 117.

    Liu W. Zhang Z. Zhang Y. Chen X. Guo S. Lei Y. (2015 a). HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway. Cancer Biol. Ther. 16 (4), 511–517.

    Not in our library10.1080/15384047.2015.1017691 (opens in a new tab)

  118. 118.

    Liu Y. C. Chang P. Y. Chao C. C. (2015 b). CITED2 silencing sensitizes cancer cells to cisplatin by inhibiting p53 trans-activation and chromatin relaxation on the ERCC1 DNA repair gene. Nucleic Acids Res. 43 (22), 10760–10781.

    Not in our library10.1093/nar/gkv934 (opens in a new tab)

  119. 119.

    Liu Y. Zheng X. Yu Q. Wang H. Tan F. Zhu Q. (2016 ). Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin. Sci. Transl. Med. 8 (348), 348ra397.

    Not in our library10.1126/scitranslmed.aaf3124 (opens in a new tab)

  120. 120.

    Liu C. W. Hua K. T. Li K. C. Kao H. F. Hong R. L. Ko J. Y. (2017 a). Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate-Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma. Mol. Cancer Ther. 16 (7), 1421–1434.

    Not in our library10.1158/1535-7163.mct-16-0567-t (opens in a new tab)

  121. 121.

    Liu W. Chen H. Wong N. Haynes W. Baker C. M. Wang X. (2017 b). Pseudohypoxia induced by miR-126 deactivation promotes migration and therapeutic resistance in renal cell carcinoma. Cancer Lett. 394, 65–75.

    Not in our library10.1016/j.canlet.2017.02.025 (opens in a new tab)

  122. 122.

    Liu Y. Niu Z. Lin X. Tian Y. (2017 c). MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1. Cancer Gene Ther. 24 (5), 208–214.

    Not in our library10.1038/cgt.2017.6 (opens in a new tab)

  123. 123.

    Liu Y. Zhu S. T. Wang X. Deng J. Li W. H. Zhang P. (2017 d). MiR-200c regulates tumor growth and chemosensitivity to cisplatin in osteosarcoma by targeting AKT2. Sci. Rep. 7 (1), 13598.

    Not in our library10.1038/s41598-017-14088-3 (opens in a new tab)

  124. 124.

    Liu J. Xing Y. Rong L. (2018 ). miR-181 regulates cisplatin-resistant non-small cell lung cancer via downregulation of autophagy through the PTEN/PI3K/AKT pathway. Oncol. Rep. 39 (4), 1631–1639.

    Not in our library10.3892/or.2018.6268 (opens in a new tab)

  125. 125.

    Ma L. Xu Y. Su J. Yu H. Kang J. Li H. (2015 a). Autophagic flux promotes cisplatin resistance in human ovarian carcinoma cells through ATP-mediated lysosomal function. Int. J. Oncol. 47 (5), 1890–1900.

    Not in our library10.3892/ijo.2015.3176 (opens in a new tab)

  126. 126.

    Ma M. Z. Chen G. Wang P. Lu W. H. Zhu C. F. Song M. (2015 b). Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism. Cancer Lett. 368 (1), 88–96.

    Not in our library10.1016/j.canlet.2015.07.031 (opens in a new tab)

  127. 127.

    Ma B. Yuan Z. Zhang L. Lv P. Yang T. Gao J. (2017 ). Long non-coding RNA AC023115.3 suppresses chemoresistance of glioblastoma by reducing autophagy. Biochim. Biophys. Acta Mol. Cell Res. 1864 (8), 1393–1404.

    Not in our library10.1016/j.bbamcr.2017.05.008 (opens in a new tab)

  128. 128.

    MacDonagh L. Gray S. G. Breen E. Cuffe S. Finn S. P. O’Byrne K. J. (2016 ). Lung cancer stem cells: The root of resistance. Cancer Lett. 372 (2), 147–156.

    Not in our library10.1016/j.canlet.2016.01.012 (opens in a new tab)

  129. 129.

    Marchenko N. D. Moll U. M. (2007 ). The role of ubiquitination in the direct mitochondrial death program of p53. Cell Cycle 6 (14), 1718–1723.

    Not in our library10.4161/cc.6.14.4503 (opens in a new tab)

  130. 130.

    Martens-de Kemp S. R. Brink A. van der Meulen I. H. de Menezes R. X. Te Beest D. E. Leemans C. R. (2017 ). The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics. Mol. Cancer Ther. 16 (3), 540–550.

    Not in our library10.1158/1535-7163.mct-16-0457 (opens in a new tab)

  131. 131.

    Martinez-Balibrea E. Martinez-Cardus A. Musulen E. Gines A. Manzano J. L. Aranda E. (2009 ). Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Int. J. Cancer 124 (12), 2905–2910.

    Not in our library10.1002/ijc.24273 (opens in a new tab)

  132. 132.

    Martinez-Rivera M. Siddik Z. H. (2012 ). Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53. Biochem. Pharmacol. 83 (8), 1049–1062.

    Not in our library10.1016/j.bcp.2011.12.026 (opens in a new tab)

  133. 133.

    Masters J. R. Thomas R. Hall A. G. Hogarth L. Matheson E. C. Cattan A. R. (1996 ). Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur. J. Cancer 32a (7), 1248–1253.

    Not in our library10.1016/0959-8049(96)00033-0 (opens in a new tab)

  134. 134.

    McKeage M. J. (1995 ). Comparative adverse effect profiles of platinum drugs. Drug Saf. 13 (4), 228–244.

    Not in our library10.2165/00002018-199513040-00003 (opens in a new tab)

  135. 135.

    Meng Y. Chen C. W. Yung M. M. H. Sun W. Sun J. Li Z. (2018 ). DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer. Cancer Lett. 428, 104–116.

    Not in our library10.1016/j.canlet.2018.04.029 (opens in a new tab)

  136. 136.

    Miow Q. H. Tan T. Z. Ye J. Lau J. A. Yokomizo T. Thiery J. P. (2015 ). Epithelial-mesenchymal status renders differential responses to cisplatin in ovarian cancer. Oncogene 34 (15), 1899–1907.

    Not in our library10.1038/onc.2014.136 (opens in a new tab)

  137. 137.

    Mizushima N. Klionsky D. J. (2007 ). Protein turnover via autophagy: implications for metabolism. Annu. Rev. Nutr. 27, 19–40.

    Not in our library10.1146/annurev.nutr.27.061406.093749 (opens in a new tab)

  138. 138.

    Muggia F. Safra T. (2014 ). ‘BRCAness’ and its implications for platinum action in gynecologic cancer. Anticancer Res. 34 (2), 551–556.

    Not in our library

  139. 139.

    Myint K. Li Y. Paxton J. McKeage M. (2015 ). Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PloS One 10 (7), e0130727.

    Not in our library10.1371/journal.pone.0130727 (opens in a new tab)

  140. 140.
    HIF-1-Dependent Reprogramming of Glucose Metabolic Pathway of Cancer Cells and Its Therapeutic Significance · 2019
    No notice
  141. 141.

    Naik P. P. Mukhopadhyay S. Panda P. K. Sinha N. Das C. K. Mishra R. (2018 ). Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD44, ABCB1 and ADAM17 in oral squamous cell carcinoma. Cell Prolif 51 (1), e12411.

    Not in our library10.1111/cpr.12411 (opens in a new tab)

  142. 142.

    Norquist B. Wurz K. A. Pennil C. C. Garcia R. Gross J. Sakai W. (2011 ). Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29 (22), 3008–3015.

    Not in our library10.1200/jco.2010.34.2980 (opens in a new tab)

  143. 143.

    Ohrvik H. Logeman B. Turk B. Reinheckel T. Thiele D. J. (2016 ). Cathepsin Protease Controls Copper and Cisplatin Accumulation via Cleavage of the Ctr1 Metal-binding Ectodomain. J. Biol. Chem. 291 (27), 13905–13916.

    Not in our library10.1074/jbc.m116.731281 (opens in a new tab)

  144. 144.

    Oien D. B. Garay T. Eckstein S. Chien J. (2017 ). Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy. Front. Pharmacol. 8, 970.

    Not in our library10.3389/fphar.2017.00970 (opens in a new tab)

  145. 145.

    Osada R. Horiuchi A. Kikuchi N. Yoshida J. Hayashi A. Ota M. (2007 ). Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum. Pathol. 38 (9), 1310–1320.

    Not in our library10.1016/j.humpath.2007.02.010 (opens in a new tab)

  146. 146.

    Ozcan M. F. Dizdar O. Dincer N. Balci S. Guler G. Gok B. (2013 ). Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy. Urol. Oncol. 31 (8), 1709–1715.

    Not in our library10.1016/j.urolonc.2012.06.014 (opens in a new tab)

  147. 147.
    Autophagic control of cell ‘stemness’ · 2013
    No notice
  148. 148.

    Pan Y. Zhang Q. Atsaves V. Yang H. Claret F. X. (2013 b). Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways. Oncogene 32 (22), 2756–2766.

    Not in our library10.1038/onc.2012.294 (opens in a new tab)

  149. 149.

    Pan J. Li X. Wu W. Xue M. Hou H. Zhai W. (2016 ). Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer Lett. 382 (1), 64–76.

    Not in our library10.1016/j.canlet.2016.08.015 (opens in a new tab)

  150. 150.

    Pan C. Jin L. Wang X. Li Y. Chun J. Boese A. C. (2019 ). Inositol-triphosphate 3-kinase B confers cisplatin resistance by regulating NOX4-dependent redox balance. J. Clin. Invest. 129 (6), 2431–2445.

    Not in our library10.1172/jci124550 (opens in a new tab)

  151. 151.

    Pannuru P. Dontula R. Khan A. A. Herbert E. Ozer H. Chetty C. (2014 ). miR-let-7f-1 regulates SPARC mediated cisplatin resistance in medulloblastoma cells. Cell Signal. 26 (10), 2193–2201.

    Not in our library10.1016/j.cellsig.2014.06.014 (opens in a new tab)

  152. 152.

    Pawlus M. R. Hu C. J. (2013 ). Enhanceosomes as integrators of hypoxia inducible factor (HIF) and other transcription factors in the hypoxic transcriptional response. Cell Signal 25 (9), 1895–1903.

    Not in our library10.1016/j.cellsig.2013.05.018 (opens in a new tab)

  153. 153.

    Pekarik V. Gumulec J. Masarik M. Kizek R. Adam V. (2013 ). Prostate cancer, miRNAs, metallothioneins and resistance to cytostatic drugs. Curr. Med. Chem. 20 (4), 534–544.

    Not in our library10.2174/0929867311320040005 (opens in a new tab)

  154. 154.

    Peng P. J. Lv B. J. Wang Z. H. Liao H. Liu Y. M. Lin Z. (2017 ). Multi-institutional prospective study of nedaplatin plus S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-containing regimens. Ther. Adv. Med. Oncol. 9 (2), 68–74.

    Not in our library10.1177/1758834016675099 (opens in a new tab)

  155. 155.

    Perland E. Fredriksson R. (2017 ). Classification Systems of Secondary Active Transporters. Trends Pharmacol. Sci. 38 (3), 305–315.

    Not in our library10.1016/j.tips.2016.11.008 (opens in a new tab)

  156. 156.
    Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5 · 2019
    No notice
  157. 157.

    Ramadoss S. Sen S. Ramachandran I. Roy S. Chaudhuri G. Farias-Eisner R. (2017 ). Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance. Oncogene 36 (46), 6508.

    Not in our library10.1038/onc.2017.331 (opens in a new tab)

  158. 158.

    Riley T. Sontag E. Chen P. Levine A. (2008 ). Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 9 (5), 402–412.

    Not in our library10.1038/nrm2395 (opens in a new tab)

  159. 159.

    Rocha C. R. Garcia C. C. Vieira D. B. Quinet A. de Andrade-Lima L. C. Munford V. (2015 ). Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. Cell Death Dis. 6, e1727.

    Not in our library10.1038/cddis.2015.101 (opens in a new tab)

  160. 160.
    Hypoxia-Inducible Factor 1α Determines Gastric Cancer Chemosensitivity via Modulation of p53 and NF-κB · 2010
    No notice
  161. 161.

    Roos W. P. Kaina B. (2013 ). DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis. Cancer Lett. 332 (2), 237–248.

    Not in our library10.1016/j.canlet.2012.01.007 (opens in a new tab)

  162. 162.

    Safaei R. Otani S. Larson B. J. Rasmussen M. L. Howell S. B. (2008 ). Transport of cisplatin by the copper efflux transporter ATP7B. Mol. Pharmacol. 73 (2), 461–468.

    Not in our library10.1124/mol.107.040980 (opens in a new tab)

  163. 163.

    Safaei R. Adams P. L. Maktabi M. H. Mathews R. A. Howell S. B. (2012 ). The CXXC motifs in the metal binding domains are required for ATP7B to mediate resistance to cisplatin. J. Inorg. Biochem. 110, 8–17.

    Not in our library10.1016/j.jinorgbio.2012.02.016 (opens in a new tab)

  164. 164.

    Samimi G. Katano K. Holzer A. K. Safaei R. Howell S. B. (2004 ). Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol. Pharmacol. 66 (1), 25–32.

    Not in our library10.1124/mol.66.1.25 (opens in a new tab)

  165. 165.

    Sawant A. Kothandapani A. Zhitkovich A. Sobol R. W. Patrick S. M. (2015 ). Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links. DNA Repair (Amst.) 35, 126–136.

    Not in our library10.1016/j.dnarep.2015.10.003 (opens in a new tab)

  166. 166.

    Schrock M. S. Batar B. Lee J. Druck T. Ferguson B. Cho J. H. (2017 ). Wwox-Brca1 interaction: role in DNA repair pathway choice. Oncogene 36 (16), 2215–2227.

    Not in our library10.1038/onc.2016.389 (opens in a new tab)

  167. 167.

    Shi L. Xu Z. Wu G. Chen X. Huang Y. Wang Y. (2017 ). Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J. BMC Cancer 17 (1), 138.

    Not in our library10.1186/s12885-017-3132-9 (opens in a new tab)

  168. 168.

    Shteingauz A. Boyango I. Naroditsky I. Hammond E. Gruber M. Doweck I. (2015 ). Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy. Cancer Res. 75 (18), 3946–3957.

    Not in our library10.1158/0008-5472.can-15-0037 (opens in a new tab)

  169. 169.

    Somasagara R. R. Spencer S. M. Tripathi K. Clark D. W. Mani C. Madeira da Silva L. (2017 ). RAD6 promotes DNA repair and stem cell signaling in ovarian cancer and is a promising therapeutic target to prevent and treat acquired chemoresistance. Oncogene 36 (48), 6680–6690.

    Not in our library10.1038/onc.2017.279 (opens in a new tab)

  170. 170.

    Somers J. Wilson L. A. Kilday J. P. Horvilleur E. Cannell I. G. Poyry T. A. (2015 ). A common polymorphism in the 5’ UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy. Genes Dev. 29 (18), 1891–1896.

    Not in our library10.1101/gad.261867.115 (opens in a new tab)

  171. 171.

    Song I. S. Savaraj N. Siddik Z. H. Liu P. Wei Y. Wu C. J. (2004 ). Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol. Cancer Ther. 3 (12), 1543–1549.

    Not in our library

  172. 172.

    Song L. Li Y. Li W. Wu S. Li Z. (2014 ). miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A). J. Cell Biochem. 115 (7), 1234–1242.

    Not in our library10.1002/jcb.24665 (opens in a new tab)

  173. 173.

    Soni S. Padwad Y. S. (2017 ). HIF-1 in cancer therapy: two decade long story of a transcription factor. Acta Oncol. 56 (4), 503–515.

    Not in our library10.1080/0284186x.2017.1301680 (opens in a new tab)

  174. 174.

    Soyano A. E. Baldeo C. Kasi P. M. (2018 ). BRCA Mutation and Its Association With Colorectal Cancer. Clin. Colorectal Cancer 17 (4), e647–e650.

    Not in our library10.1016/j.clcc.2018.06.006 (opens in a new tab)

  175. 175.

    Spada F. Antonuzzo L. Marconcini R. Radice D. Antonuzzo A. Ricci S. (2016 ). Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors. Neuroendocrinology 103 (6), 806–814.

    Not in our library10.1159/000444087 (opens in a new tab)

  176. 176.
    A phosphotyrosine switch regulates organic cation transporters · 2016
    Not checked
  177. 177.

    Steinbichler T. B. Dudas J. Skvortsov S. Ganswindt U. Riechelmann H. Skvortsova,. I. I. (2018 ). Therapy resistance mediated by cancer stem cells. Semin. Cancer Biol. 53, 156–167.

    Not in our library10.1016/j.semcancer.2018.11.006 (opens in a new tab)

  178. 178.

    Stransky N. Egloff A. M. Tward A. D. Kostic A. D. Cibulskis K. Sivachenko A. (2011 ). The mutational landscape of head and neck squamous cell carcinoma. Science 333 (6046), 1157–1160.

    Not in our library10.1126/science.1208130 (opens in a new tab)

  179. 179.

    Sui C. Meng F. Li Y. Jiang Y. (2015 ). miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression. J. Transl. Med. 13, 132.

    Not in our library10.1186/s12967-015-0488-y (opens in a new tab)

  180. 180.

    Sullivan I. Salazar J. Majem M. Pallares C. Del Rio E. Paez D. (2014 ). Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Lett. 353 (2), 160–166.

    Not in our library10.1016/j.canlet.2014.07.023 (opens in a new tab)

  181. 181.

    Sun Y. Guan Z. Liang L. Cheng Y. Zhou J. Li J. (2016 ). NF-kappaB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression. Int. J. Oncol. 48 (1), 225–234.

    Not in our library10.3892/ijo.2015.3256 (opens in a new tab)

  182. 182.

    Sun C. Wang F. J. Zhang H. G. Xu X. Z. Jia R. C. Yao L. (2017 a). miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-beta/Smad4 pathway. World J. Gastroenterol. 23 (10), 1816–1827.

    Not in our library10.3748/wjg.v23.i10.1816 (opens in a new tab)

  183. 183.

    Sun J. Pan L. M. Chen L. B. Wang Y. (2017 b). LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis. Cell Cycle 16 (21), 2100–2107.

    Not in our library10.1080/15384101.2017.1361071 (opens in a new tab)

  184. 184.

    Sun J. Cai X. Yung M. M. Zhou W. Li J. Zhang Y. (2019 ). miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene 38 (4), 564–580.

    Not in our library10.1038/s41388-018-0459-x (opens in a new tab)

  185. 185.

    Surowiak P. Materna V. Kaplenko I. Spaczynski M. Dolinska-Krajewska B. Gebarowska E. (2006 ). ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin. Cancer Res. 12 (23), 7149–7158.

    Not in our library10.1158/1078-0432.ccr-06-0564 (opens in a new tab)

  186. 186.

    Takekuma M. Shimokawa M. Nishio S. Omi H. Tabata T. Takei Y. (2018 ). Phase II study of adjuvant chemotherapy with paclitaxel and nedaplatin for uterine cervical cancer with lymph node metastasis. Cancer Sci. 109 (5), 1602–1608.

    Not in our library10.1111/cas.13577 (opens in a new tab)

  187. 187.

    Tan S. Shi H. Ba M. Lin S. Tang H. Zeng X. (2016 ). miR-409-3p sensitizes colon cancer cells to oxaliplatin by inhibiting Beclin-1-mediated autophagy. Int. J. Mol. Med. 37 (4), 1030–1038.

    Not in our library10.3892/ijmm.2016.2492 (opens in a new tab)

  188. 188.

    Taniguchi K. Wada M. Kohno K. Nakamura T. Kawabe T. Kawakami M. (1996 ). A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res. 56 (18), 4124–4129.

    Not in our library

  189. 189.
    Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway · 2016
    No notice
  190. 190.

    Tariba B. Zivkovic T. Krasnici N. Marijic V. F. Erk M. Gamulin M. (2015 ). Serum metallothionein in patients with testicular cancer. Cancer Chemother. Pharmacol. 75 (4), 813–820.

    Not in our library10.1007/s00280-015-2702-2 (opens in a new tab)

  191. 191.

    Ushijima R. Takayama K. Izumi M. Harada T. Horiuchi Y. Uchino J. (2007 ). Immunohistochemical expression of MRP2 and clinical resistance to platinum-based chemotherapy in small cell lung cancer. Anticancer Res. 27 (6c), 4351–4358.

    Not in our library

  192. 192.

    van den Berghe P. V. Folmer D. E. Malingre H. E. van Beurden E. Klomp A. E. van de Sluis B. (2007 ). Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake. Biochem. J. 407 (1), 49–59.

    Not in our library10.1042/bj20070705 (opens in a new tab)

  193. 193.

    van Jaarsveld M. T. van Kuijk P. F. Boersma A. W. Helleman J. van I. W. F. Mathijssen R. H. (2015 ). miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. Mol. Cancer 14, 196.

    Not in our library10.1186/s12943-015-0464-4 (opens in a new tab)

  194. 194.

    Vassilev L. T. Vu B. T. Graves B. Carvajal D. Podlaski F. Filipovic Z. (2004 ). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 (5659), 844–848.

    Not in our library10.1126/science.1092472 (opens in a new tab)

  195. 195.

    Wang X. Jiang P. Wang P. Yang C. S. Wang X. Feng Q. (2015 ). EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer. PloS One 10 (4), e0125402.

    Not in our library10.1371/journal.pone.0125402 (opens in a new tab)

  196. 196.

    Wang J. Zhou J. Y. Kho D. Reiners J. J. Jr. Wu G. S. (2016 a). Role for DUSP1 (dual-specificity protein phosphatase 1) in the regulation of autophagy. Autophagy 12 (10), 1791–1803.

    Not in our library10.1080/15548627.2016.1203483 (opens in a new tab)

  197. 197.

    Wang W. Kryczek I. Dostal L. Lin H. Tan L. Zhao L. (2016 b). Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer. Cell 165 (5), 1092–1105.

    Not in our library10.1016/j.cell.2016.04.009 (opens in a new tab)

  198. 198.

    Wang X. Zhu W. Zhao X. Wang P. (2016 c). miR-133a enhances the sensitivity of Hep-2 cells and vincristine-resistant Hep-2v cells to cisplatin by downregulating ATP7B expression. Int. J. Mol. Med. 37 (6), 1636–1642.

    Not in our library10.3892/ijmm.2016.2569 (opens in a new tab)

  199. 199.

    Wang S. F. Wung C. H. Chen M. S. Chen C. F. Yin P. H. Yeh T. S. (2018 ). Activated integrated stress response induced by salubrinal promotes cisplatin resistance in human gastric cancer cells via enhanced xCT expression and glutathione biosynthesis. Int. J. Mol. Sci. 19 (11), 3389.

    Not in our library10.3390/ijms19113389 (opens in a new tab)

  200. 200.

    Wang N. Song L. Xu Y. Zhang L. Wu Y. Guo J. (2019 a). Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling. EBioMedicine 47, 65–77.

    Not in our library10.1016/j.ebiom.2019.08.057 (opens in a new tab)

  201. 201.

    Wang Z. Deng Z. Zhu G. (2019 b). Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment. Dalton Trans. 48 (8), 2536–2544.

    Not in our library10.1039/c8dt03923b (opens in a new tab)

  202. 202.

    Wang Z. Liu G. Jiang J. (2019 c). Profiling of apoptosis- and autophagy-associated molecules in human lung cancer A549 cells in response to cisplatin treatment using stable isotope labeling with amino acids in cell culture. Int. J. Oncol. 54 (3), 1071–1085.

    Not in our library10.3892/ijo.2019.4690 (opens in a new tab)

  203. 203.

    Wanzel M. Vischedyk J. B. Gittler M. P. Gremke N. Seiz J. R. Hefter M. (2016 ). CRISPR-Cas9-based target validation for p53-reactivating model compounds. Nat. Chem. Biol. 12 (1), 22–28.

    Not in our library10.1038/nchembio.1965 (opens in a new tab)

  204. 204.

    Wheate N. J. Walker S. Craig G. E. Oun R. (2010 ). The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 39 (35), 8113–8127.

    Not in our library10.1039/c0dt00292e (opens in a new tab)

  205. 205.

    Wigerup C. Pahlman S. Bexell D. (2016 ). Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol. Ther. 164, 152–169.

    Not in our library10.1016/j.pharmthera.2016.04.009 (opens in a new tab)

  206. 206.

    Woynarowski J. M. Faivre S. Herzig M. C. Arnett B. Chapman W. G. Trevino A. V. (2000 ). Oxaliplatin-induced damage of cellular DNA. Mol. Pharmacol. 58 (5), 920–927.

    Not in our library10.1124/mol.58.5.920 (opens in a new tab)

  207. 207.

    Wu B. Cui J. Yang X. M. Liu Z. Y. Song F. Li L. (2017 ). Cytoplasmic fragment of CD147 generated by regulated intramembrane proteolysis contributes to HCC by promoting autophagy. Cell Death Dis. 8 (7), e2925.

    Not in our library10.1038/cddis.2017.251 (opens in a new tab)

  208. 208.

    Wynne P. Newton C. Ledermann J. A. Olaitan A. Mould T. A. Hartley J. A. (2007 ). Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br. J. Cancer 97 (7), 927–933.

    Not in our library10.1038/sj.bjc.6603973 (opens in a new tab)

  209. 209.

    Xi Z. Si J. Nan J. (2019 ). LncRNA MALAT1 potentiates autophagyassociated cisplatin resistance by regulating the microRNA30b/autophagyrelated gene 5 axis in gastric cancer. Int. J. Oncol. 54 (1), 239–248.

    Not in our library10.3892/ijo.2018.4609 (opens in a new tab)

  210. 210.

    Xiao M. Cai J. Cai L. Jia J. Xie L. Zhu Y. (2017 ). Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair. J. Ovarian Res. 10 (1), 24.

    Not in our library10.1186/s13048-017-0321-8 (opens in a new tab)

  211. 211.

    Xiao F. Li Y. Wan Y. Xue M. (2018 ). MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B. Cancer Chemother. Pharmacol. 81 (5), 935–947.

    Not in our library10.1007/s00280-018-3548-1 (opens in a new tab)

  212. 212.

    Xie X. He G. Siddik Z. H. (2017 ). Functional Activation of Mutant p53 by Platinum Analogues in Cisplatin-Resistant Cells Is Dependent on Phosphorylation. Mol. Cancer Res. 15 (3), 328–339.

    Not in our library10.1158/1541-7786.mcr-16-0257-t (opens in a new tab)

  213. 213.

    Xu W. Chen Q. Wang Q. Sun Y. Wang S. Li A. (2014 ). JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells. Cell Death Dis. 5, e1551.

    Not in our library10.1038/cddis.2014.517 (opens in a new tab)

  214. 214.

    Xu Y. Gao W. Zhang Y. Wu S. Liu Y. Deng X. (2018 ). ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells. Int. J. Oncol. 53 (3), 1055–1068.

    Not in our library10.3892/ijo.2018.4476 (opens in a new tab)

  215. 215.

    Yamamoto M. Tsujinaka T. Shiozaki H. Doki Y. Tamura S. Inoue M. (1999 ). Metallothionein expression correlates with the pathological response of patients with esophageal cancer undergoing preoperative chemoradiation therapy. Oncology 56 (4), 332–337.

    Not in our library10.1159/000011988 (opens in a new tab)

  216. 216.

    Yamasaki M. Makino T. Masuzawa T. Kurokawa Y. Miyata H. Takiguchi S. (2011 ). Role of multidrug resistance protein 2 (MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma. Br. J. Cancer 104 (4), 707–713.

    Not in our library10.1038/sj.bjc.6606071 (opens in a new tab)

  217. 217.

    Yaneff A. Sahores A. Gomez N. Carozzo A. Shayo C. Davio C. (2019 ). MRP4/ABCC4 As a New Therapeutic Target: Meta-Analysis to Determine cAMP Binding Sites as a Tool for Drug Design. Curr. Med. Chem. 26 (7), 1270–1307.

    Not in our library10.2174/0929867325666171229133259 (opens in a new tab)

  218. 218.

    Yang H. Z. Ma Y. Zhou Y. Xu L. M. Chen X. J. Ding W. B. (2015 ). Autophagy contributes to the enrichment and survival of colorectal cancer stem cells under oxaliplatin treatment. Cancer Lett. 361 (1), 128–136.

    Not in our library10.1016/j.canlet.2015.02.045 (opens in a new tab)

  219. 219.

    Yang L. Lin Z. Wang Y. Gao S. Li Q. Li C. (2018 ). MiR-5100 increases the cisplatin resistance of the lung cancer stem cells by inhibiting the Rab6. Mol. Carcinog. 57 (3), 419–428.

    Not in our library10.1002/mc.22765 (opens in a new tab)

  220. 220.

    Yang G. Fu Y. Lu X. Wang M. Dong H. Li Q. (2019 ). miR34a regulates the chemosensitivity of retinoblastoma cells via modulation of MAGEA/p53 signaling. Int. J. Oncol. 54 (1), 177–187.

    Not in our library10.3892/ijo.2018.4613 (opens in a new tab)

  221. 221.

    Yokoo S. Yonezawa A. Masuda S. Fukatsu A. Katsura T. Inui K. (2007 ). Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem. Pharmacol. 74 (3), 477–487.

    Not in our library10.1016/j.bcp.2007.03.004 (opens in a new tab)

  222. 222.

    Yonezawa A. Masuda S. Yokoo S. Katsura T. Inui K. (2006 ). Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther. 319 (2), 879–886.

    Not in our library10.1124/jpet.106.110346 (opens in a new tab)

  223. 223.

    Yu L. Gu C. Zhong D. Shi L. Kong Y. Zhou Z. (2014 ). Induction of autophagy counteracts the anticancer effect of cisplatin in human esophageal cancer cells with acquired drug resistance. Cancer Lett. 355 (1), 34–45.

    Not in our library10.1016/j.canlet.2014.09.020 (opens in a new tab)

  224. 224.

    Zarogoulidis P. Petanidis S. Kioseoglou E. Domvri K. Anestakis D. Zarogoulidis K. (2015 ). MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. Cell Signal 27 (8), 1576–1588.

    Not in our library10.1016/j.cellsig.2015.04.009 (opens in a new tab)

  225. 225.

    Zhang Y. H. Wu Q. Xiao X. Y. Li D. W. Wang X. P. (2010 ). Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell. Cancer Lett. 291 (1), 76–82.

    Not in our library10.1016/j.canlet.2009.10.003 (opens in a new tab)

  226. 226.

    Zhang X. W. Bu P. Liu L. Zhang X. Z. Li J. (2015 ). Overexpression of long non-coding RNA PVT1 in gastric cancer cells promotes the development of multidrug resistance. Biochem. Biophys. Res. Commun. 462 (3), 227–232.

    Not in our library10.1016/j.bbrc.2015.04.121 (opens in a new tab)

  227. 227.

    Zhang Q. Shi J. Yuan F. Wang H. Fu W. Pan J. (2016 a). Higher expression of XPF is a critical factor in intrinsic chemotherapy resistance of human renal cell carcinoma. Int. J. Cancer 139 (12), 2827–2837.

    Not in our library10.1002/ijc.30396 (opens in a new tab)

  228. 228.

    Zhang Y. Xu W. Ni P. Li A. Zhou J. Xu S. (2016 b). MiR-99a and MiR-491 Regulate Cisplatin Resistance in Human Gastric Cancer Cells by Targeting CAPNS1. Int. J. Biol. Sci. 12 (12), 1437–1447.

    Not in our library10.7150/ijbs.16529 (opens in a new tab)

  229. 229.

    Zhang L. Wang Y. Li X. Xia X. Li N. He R. (2017 ). ZBTB7A Enhances Osteosarcoma Chemoresistance by Transcriptionally Repressing lncRNALINC00473-IL24 Activity. Neoplasia 19 (11), 908–918.

    Not in our library10.1016/j.neo.2017.08.008 (opens in a new tab)

  230. 230.

    Zhao L. Li W. Zhou Y. Zhang Y. Huang S. Xu X. (2015 ). The overexpression and nuclear translocation of Trx-1 during hypoxia confers on HepG2 cells resistance to DDP, and GL-V9 reverses the resistance by suppressing the Trx-1/Ref-1 axis. Free Radic. Biol. Med. 82, 29–41.

    Not in our library10.1016/j.freeradbiomed.2015.01.014 (opens in a new tab)

  231. 231.

    Zhao Q. Tan B. B. Li Y. Fan L. Q. Yang P. G. Tian Y. (2016 ). Enhancement of Drug Sensitivity by Knockdown of HIF-1alpha in Gastric Carcinoma Cells. Oncol. Res. 23 (3), 129–136.

    Not in our library10.3727/096504015x14500513118029 (opens in a new tab)

  232. 232.

    Zhao X. Li X. Zhou L. Ni J. Yan W. Ma R. (2018 a). LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3. Cancer Sci. 109 (10), 3068–3079.

    Not in our library10.1111/cas.13764 (opens in a new tab)

  233. 233.

    Zhao Y. Ma K. Yang S. Zhang X. Wang F. Zhang X. (2018 b). MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway. Int. J. Oncol. 53 (2), 644–658.

    Not in our library10.3892/ijo.2018.4409 (opens in a new tab)

  234. 234.

    Zhen Y. Fang W. Zhao M. Luo R. Liu Y. Fu Q. (2017 ). miR-374a-CCND1-pPI3K/AKT-c-JUN feedback loop modulated by PDCD4 suppresses cell growth, metastasis, and sensitizes nasopharyngeal carcinoma to cisplatin. Oncogene 36 (2), 275–285.

    Not in our library10.1038/onc.2016.201 (opens in a new tab)

  235. 235.
    The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer · 2016
    No notice
  236. 236.

    Zheng D. Wu W. Dong N. Jiang X. Xu J. Zhan X. (2017 a). Mxd1 mediates hypoxia-induced cisplatin resistance in osteosarcoma cells by repression of the PTEN tumor suppressor gene. Mol. Carcinog. 56 (10), 2234–2244.

    Not in our library10.1002/mc.22676 (opens in a new tab)

  237. 237.
    Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells · 2017
    No notice
  238. 238.

    Zhong L. Z. Xu H. Y. Zhao Z. M. Zhang G. M. Lin F. W. (2018 ). Comparison of efficacy and toxicity between nedaplatin and cisplatin in treating malignant pleural effusion. Onco. Targets Ther. 11, 5509–5512.

    Not in our library10.2147/ott.s168391 (opens in a new tab)

  239. 239.

    Zhou B. Sun C. Li N. Shan W. Lu H. Guo L. (2016 a). Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways. Int. J. Oncol. 48 (5), 2087–2097.

    Not in our library10.3892/ijo.2016.3442 (opens in a new tab)

  240. 240.

    Zhou P. Ma L. Zhou J. Jiang M. Rao E. Zhao Y. (2016 b). miR-17-92 plays an oncogenic role and conveys chemo-resistance to cisplatin in human prostate cancer cells. Int. J. Oncol. 48 (4), 1737–1748.

    Not in our library10.3892/ijo.2016.3392 (opens in a new tab)

  241. 241.

    Zhou F. Zhu L. Wang K. Murray M. (2017 ). Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition. Adv. Drug Deliv. Rev. 116, 21–36.

    Not in our library10.1016/j.addr.2016.06.004 (opens in a new tab)

  242. 242.

    Zhou W. Sun W. Yung M. M. H. Dai S. Cai Y. Chen C. W. (2018 ). Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance. Oncogene 37 (29), 3981–3997.

    Not in our library10.1038/s41388-018-0238-8 (opens in a new tab)

  243. 243.

    Zhu X. Ji M. Han Y. Guo Y. Zhu W. Gao F. (2017 ). PGRMC1-dependent autophagy by hyperoside induces apoptosis and sensitizes ovarian cancer cells to cisplatin treatment. Int. J. Oncol. 50 (3), 835–846.

    Not in our library10.3892/ijo.2017.3873 (opens in a new tab)

  244. 244.

    Zhu Z. Du S. Du Y. Ren J. Ying G. Yan Z. (2018 ). Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis. J. Neurochem. 144 (1), 93–104.

    Not in our library10.1111/jnc.14250 (opens in a new tab)

  245. 245.

    Zhu Q. Yu L. Qin Z. Chen L. Hu H. Zheng X. (2019 ). Regulation of OCT2 transcriptional repression by histone acetylation in renal cell carcinoma. Epigenetics 14 (8), 791–803.

    Not in our library10.1080/15592294.2019.1615354 (opens in a new tab)

  246. 246.

    Zimmermann T. Burda J. V. (2010 ). Cisplatin interaction with amino acids cysteine and methionine from gas phase to solutions with constant pH. Interdiscip. Sci. 2 (1), 98–114.

    Not in our library10.1007/s12539-010-0094-x (opens in a new tab)

Cited by papers we hold 2

Questions about this paper

We email you if it is retracted, withdrawn, corrected or flagged.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.